58 results on '"Barbara Fetterman"'
Search Results
2. Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology
- Author
-
Nancy Poitras, Brian Befano, Noorie Hyun, William Wheeler, Tina Raine-Bennett, Barbara Fetterman, Robin E Stamps, Nicolas Wentzensen, Kai Yu, Julia C. Gage, Han Zhang, Philip E. Castle, Mark Schiffman, and Thomas Lorey
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Cytological Techniques ,Uterine Cervical Neoplasms ,Risk Assessment ,California ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,Cytology ,medicine ,Humans ,Mass Screening ,Early Detection of Cancer ,Mass screening ,Neoplasm Staging ,Colposcopy ,Framingham Risk Score ,Cervical screening ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Papillomavirus Infections ,Articles ,Triage ,030104 developmental biology ,ROC Curve ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Risk assessment ,Algorithms ,Record linkage - Abstract
BACKGROUND: State-of-the-art cervical cancer prevention includes human papillomavirus (HPV) vaccination among adolescents and screening/treatment of cervical precancer (CIN3/AIS and, less strictly, CIN2) among adults. HPV testing provides sensitive detection of precancer but, to reduce overtreatment, secondary “triage” is needed to predict women at highest risk. Those with the highest-risk HPV types or abnormal cytology are commonly referred to colposcopy; however, expert cytology services are critically lacking in many regions. METHODS: To permit completely automatable cervical screening/triage, we designed and validated a novel triage method, a cytologic risk score algorithm based on computer-scanned liquid-based slide features (FocalPoint, BD, Burlington, NC). We compared it with abnormal cytology in predicting precancer among 1839 women testing HPV positive (HC2, Qiagen, Germantown, MD) in 2010 at Kaiser Permanente Northern California (KPNC). Precancer outcomes were ascertained by record linkage. As additional validation, we compared the algorithm prospectively with cytology results among 243 807 women screened at KPNC (2016–2017). All statistical tests were two-sided. RESULTS: Among HPV-positive women, the algorithm matched the triage performance of abnormal cytology. Combined with HPV16/18/45 typing (Onclarity, BD, Sparks, MD), the automatable strategy referred 91.7% of HPV-positive CIN3/AIS cases to immediate colposcopy while deferring 38.4% of all HPV-positive women to one-year retesting (compared with 89.1% and 37.4%, respectively, for typing and cytology triage). In the 2016–2017 validation, the predicted risk scores strongly correlated with cytology (P < .001). CONCLUSIONS: High-quality cervical screening and triage performance is achievable using this completely automated approach. Automated technology could permit extension of high-quality cervical screening/triage coverage to currently underserved regions.
- Published
- 2018
3. Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting
- Author
-
Barbara Fetterman, Mark Schiffman, Philip E. Castle, Nancy E. Poitras, Katharine A. Rendle, Li C. Cheung, Walter Kinney, and Thomas Lorey
- Subjects
Adult ,medicine.medical_specialty ,Epidemiology ,Ethnic group ,Uterine Cervical Neoplasms ,California ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Cytology ,medicine ,Humans ,Mass Screening ,Longitudinal Studies ,030212 general & internal medicine ,Human papillomavirus ,Papillomaviridae ,Early Detection of Cancer ,Cervical screening ,Obstetrics ,business.industry ,Medical record ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,Middle Aged ,Uterine Cervical Dysplasia ,030220 oncology & carcinogenesis ,Cohort ,Managed care ,Female ,Guideline Adherence ,business ,Cohort study - Abstract
Although guidelines have recommended extended interval cervical screening using concurrent human papillomavirus (HPV) and cytology ("cotesting") for over a decade, little is known about its adoption into routine care. Using longitudinal medical record data (2003-2015) from Kaiser Permanente Northern California (KPNC), which adopted triennial cotesting in 2003, we examined adherence to extended interval screening. We analyzed predictors of screening intervals among 491,588 women undergoing routine screening, categorizing interval length into early (
- Published
- 2018
4. Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy
- Author
-
Nancy Poitras, Brian Befano, Nicolas Wentzensen, Maria Demarco, Philip E. Castle, Thomas Lorey, Mark Schiffman, Barbara Fetterman, Walter Kinney, and Li C. Cheung
- Subjects
Adult ,medicine.medical_specialty ,Population ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,urologic and male genital diseases ,CIN 3+ ,Risk Assessment ,California ,postcolposcopy surveillance ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,education ,Normal cytology ,neoplasms ,risk ,Aged ,Neoplasm Staging ,Colposcopy ,Cervical cancer ,education.field_of_study ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Original Research Articles: Cervix and HPV ,Obstetrics ,business.industry ,colposcopy ,Papillomavirus Infections ,Obstetrics and Gynecology ,virus diseases ,General Medicine ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Current management ,management guidelines ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Female ,Risk assessment ,Large group ,business ,Precancerous Conditions - Abstract
OBJECTIVE To inform impending postcolposcopy guidelines, this analysis examined the subsequent risk of CIN 3+ among women with a grade lower than CIN 2 (< CIN 2) colposcopy results, taking into account the referring results that brought them to colposcopy and cotest results postcolposcopy. METHODS We analyzed 107,005 women from 25 to 65 years old, recommended for colposcopy at Kaiser Permanente Northern California. We estimated absolute risks of CIN 3+ among women: (1) recommended for colposcopy (precolposcopy), (2) following colposcopy and with histology results < CIN 2 (postcolposcopy), and (3) with cotest results 12 months after a < CIN 2 colposcopy (return cotest). RESULTS After colposcopy showing < CIN 2 (n = 69,790; 87% of the women at colposcopy), the 1-year risk of CIN 3+ was 1.2%, compared with 6.3% at the time of colposcopy recommendation. Negative cotest results 1 year after colposcopy identified a large group (37.1%) of women whose risk of CIN 3+ (i.e.
- Published
- 2018
5. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening
- Author
-
Thomas Lorey, Hormuzd A. Katki, Mark Schiffman, Barbara Fetterman, Walter Kinney, Nancy Poitras, Brian Befano, Julia C. Gage, Li C. Cheung, Nicolas Wentzensen, Philip E. Castle, and John Schussler
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Cytodiagnosis ,Uterine Cervical Neoplasms ,Cervix Uteri ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Cytology ,medicine ,Humans ,Mass Screening ,Human papillomavirus ,Stage (cooking) ,Papillomaviridae ,Early Detection of Cancer ,Aged ,Aged, 80 and over ,Vaginal Smears ,030219 obstetrics & reproductive medicine ,Cervical screening ,Obstetrics ,business.industry ,Papillomavirus Infections ,Cancer ,Articles ,Middle Aged ,Prognosis ,medicine.disease ,Hpv testing ,Oncology ,030220 oncology & carcinogenesis ,Predictive value of tests ,Female ,Histopathology ,business ,Precancerous Conditions - Abstract
Background The main goal of cervical screening programs is to detect and treat precancer before cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer. However, reports of rare HPV-negative, cytology-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs. Methods We quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente Northern California (KPNC), where 1 208 710 women age 30 years and older have undergone triennial cervical cotesting since 2003. Screening histories preceding cervical cancers (n = 623) and precancers (n = 5369) were examined to assess the relative contribution of the cytology and HPV test components in identifying cases. The performances of HPV testing and cytology were compared using contingency table methods, general estimating equation models, and nonparametric statistics; all statistical tests were two-sided. Results HPV testing identified more women subsequently diagnosed with cancer (P < .001) and precancer (P < .001) than cytology. HPV testing was statistically significantly more likely to be positive for cancer at any time point (P < .001), except within 12 months (P = .10). HPV-negative/cytology-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%); these cancers were more likely to be regional or distant stage with squamous histopathology than other cases. Given the rarity of cancers among screened women, the contribution of cytology to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67.9%) of women found to have cancer during 10 years of follow-up at KPNC were detected by the first cotest performed. Conclusions The added sensitivity of cotesting vs HPV alone for detection of treatable cancer affected extremely few women.
- Published
- 2017
6. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines
- Author
-
Nancy Poitras, Brian Befano, Mark Schiffman, Barbara Fetterman, Walter Kinney, Li C. Cheung, Nicolas Wentzensen, Philip E. Castle, Maria Demarco, Richard S. Guido, and Thomas Lorey
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,cervical cancer ,Cytological Techniques ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Virology ,Cytology ,Internal medicine ,medicine ,Humans ,Mass Screening ,Papillomaviridae ,Aged ,Gynecology ,Colposcopy ,Cervical cancer ,030219 obstetrics & reproductive medicine ,Cervical screening ,Original Research Articles: Cervix and HPV ,medicine.diagnostic_test ,business.industry ,screening ,Obstetrics and Gynecology ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Squamous intraepithelial lesion ,management guidelines ,030220 oncology & carcinogenesis ,Female ,business ,Risk assessment - Abstract
As a foundation for the next guidelines revision, we confirmed with additional precision the risk estimates previously reported for combinations of human papillomavirus and cytology screening., Objectives The next round of the American Society for Colposcopy and Cervical Pathology (ASCCP)-sponsored cervical cancer screening and management guidelines will recommend clinical actions based on risk, rather than test-based algorithms. This article gives preliminary risk estimates for the screening setting, showing combinations of the 2 most important predictors, human papillomavirus (HPV) status and cytology result. Materials and Methods Among 1,262,713 women aged 25 to 77 years co-tested with HC2 (Qiagen) and cytology at Kaiser Permanente Northern California, we estimated 0–5-year cumulative risk of cervical intraepithelial neoplasia (CIN) 2+, CIN 3+, and cancer for combinations of cytology (negative for intraepithelial lesion or malignancy [NILM], atypical squamous cells of undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL], atypical squamous cells cannot exclude HSIL [ASC-H], high-grade squamous intraepithelial lesion [HSIL], atypical glandular cells [AGC]) and HPV status. Results Ninety percent of screened women had HPV-negative NILM and an extremely low risk of subsequent cancer. Five-year risks of CIN 3+ were lower after HPV negativity (0.12%) than after NILM (0.25%). Among HPV-negative women, 5-year risks for CIN 3+ were 0.10% for NILM, 0.44% for ASC-US, 1.8% for LSIL, 3.0% for ASC-H, 1.2% for AGC, and 29% for HSIL+ cytology (which was very rare). Among HPV-positive women, 5-year risks were 4.0% for NILM, 6.8% for ASC-US, 6.1% for LSIL, 28% for ASC-H, 30% for AGC, and 50% for HSIL+ cytology. Conclusions As a foundation for the next guidelines revision, we confirmed with additional precision the risk estimates previously reported for combinations of HPV and cytology. Future analyses will estimate risks for women being followed in colposcopy clinic and posttreatment and will consider the role of risk modifiers such as age, HPV vaccine status, HPV type, and screening and treatment history.
- Published
- 2017
7. Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records
- Author
-
Qing Pan, Li C. Cheung, Hormuzd A. Katki, Philip E. Castle, Barbara Fetterman, Mark Schiffman, Thomas Lorey, and Noorie Hyun
- Subjects
Adult ,Statistics and Probability ,Epidemiology ,Cost-Benefit Analysis ,Uterine Cervical Neoplasms ,Disease ,Logistic regression ,01 natural sciences ,Article ,California ,Statistics, Nonparametric ,Cohort Studies ,010104 statistics & probability ,03 medical and health sciences ,0302 clinical medicine ,Covariate ,Prevalence ,medicine ,Electronic Health Records ,Humans ,0101 mathematics ,Survival analysis ,Aged ,Cervical cancer ,business.industry ,Incidence ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Survival Analysis ,Logistic Models ,030220 oncology & carcinogenesis ,Cohort ,Female ,business ,Algorithms ,Papanicolaou Test ,Demography ,Cohort study - Abstract
For cost-effectiveness and efficiency, many large-scale general-purpose cohort studies are being assembled within large health-care providers who use electronic health records. Two key features of such data are that incident disease is interval-censored between irregular visits and there can be pre-existing (prevalent) disease. Because prevalent disease is not always immediately diagnosed, some disease diagnosed at later visits are actually undiagnosed prevalent disease. We consider prevalent disease as a point mass at time zero for clinical applications where there is no interest in time of prevalent disease onset. We demonstrate that the naive Kaplan-Meier cumulative risk estimator underestimates risks at early time points and overestimates later risks. We propose a general family of mixture models for undiagnosed prevalent disease and interval-censored incident disease that we call prevalence-incidence models. Parameters for parametric prevalence-incidence models, such as the logistic regression and Weibull survival (logistic-Weibull) model, are estimated by direct likelihood maximization or by EM algorithm. Non-parametric methods are proposed to calculate cumulative risks for cases without covariates. We compare naive Kaplan-Meier, logistic-Weibull, and non-parametric estimates of cumulative risk in the cervical cancer screening program at Kaiser Permanente Northern California. Kaplan-Meier provided poor estimates while the logistic-Weibull model was a close fit to the non-parametric. Our findings support our use of logistic-Weibull models to develop the risk estimates that underlie current US risk-based cervical cancer screening guidelines. Published 2017. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
- Published
- 2017
8. Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer
- Author
-
Julia C. Gage, Mark Schiffman, Barbara Fetterman, John Schussler, Walter Kinney, Philip E. Castle, Nancy Poitras, Brian Befano, Thomas Lorey, Maria Demarco, Nicolas Wentzensen, Hormuzd A. Katki, Li C. Cheung, Tina Raine-Bennett, and Megan A. Clarke
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Overweight ,Lower risk ,California ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Medicine ,Humans ,030212 general & internal medicine ,Obesity ,Papillomaviridae ,Early Detection of Cancer ,Retrospective Studies ,Cervical cancer ,Cervical screening ,business.industry ,Obstetrics ,Papillomavirus Infections ,Age Factors ,Cancer ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,Oncology ,030220 oncology & carcinogenesis ,DNA, Viral ,Female ,Underweight ,medicine.symptom ,business ,RAPID COMMUNICATION ,Body mass index ,Precancerous Conditions - Abstract
Purpose Obesity has been inconsistently linked to increased cervical cancer incidence and mortality; however, the effect of obesity on cervical screening has not been explored. We investigated the hypothesis that increased body mass might decrease detection of cervical precancer and increase risk of cervical cancer even in women undergoing state-of-the-art screening. Methods We conducted a retrospective cohort study of 944,227 women age 30 to 64 years who underwent cytology and human papillomavirus DNA testing (ie, cotesting) at Kaiser Permanente Northern California (January 2003 to December 2015). Body mass index was categorized as normal/underweight (< 25 kg/m2), overweight (25 to < 30 kg/m2), or obese (≥ 30 kg/m2). We estimated 5-year cumulative risks of cervical precancer and cancer by category of body mass index using logistic Weibull survival models. Results We observed lower risk of cervical precancer (n = 4,489) and higher risk of cervical cancer (n = 490) with increasing body mass index. Specifically, obese women had the lowest 5-year risk of precancer (0.51%; 95% CI, 0.48% to 0.54% v 0.73%; 95% CI, 0.70% to 0.76% in normal/underweight women; P trend < .001). In contrast, obese women had the highest 5-year risk of cancer (0.083%; 95% CI, 0.072% to 0.096% v 0.056%; 95% CI, 0.048% to 0.066% in normal/underweight women; P trend < .001). Results were consistent in subgroups defined by age (30 to 49 v 50 to 64 years), human papillomavirus status (positive v negative), and histologic subtype (glandular v squamous). Approximately 20% of cervical cancers could be attributed to overweight or obesity in the women in our study who underwent routine cervical screening. Conclusion In this large, screened population, overweight and obese women had an increased risk of cervical cancer, likely because of underdiagnosis of cervical precancer. Improvements in equipment and/or technique to assure adequate sampling and visualization of women with elevated body mass might reduce cervical cancer incidence.
- Published
- 2018
9. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing
- Author
-
Mark Schiffman, Maria Demarco, Barbara Fetterman, Julia C. Gage, Tina Raine-Bennett, Nancy E. Poitras, Cher M. Dallal, Olivia Carter-Pokras, Philip E. Castle, Nicolas Wentzensen, Noorie Hyun, Thomas Lorey, Jie Chen, Brian Befano, and Xin He
- Subjects
Microbiology (medical) ,Oncology ,Adult ,medicine.medical_specialty ,Genotype ,Epidemiology ,Uterine Cervical Neoplasms ,Cervix Uteri ,Sensitivity and Specificity ,Human Papillomavirus DNA Tests ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Typing ,Cervix ,Genotyping ,Papillomaviridae ,Early Detection of Cancer ,Aged ,Cervical cancer ,Cervical screening ,business.industry ,Papillomavirus Infections ,Becton dickinson ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,United States ,medicine.anatomical_structure ,Cross-Sectional Studies ,030220 oncology & carcinogenesis ,Female ,business ,Kappa - Abstract
As cervical cancer screening shifts from cytology to human papillomavirus (HPV) testing, a major question is the clinical value of identifying individual HPV types. We aimed to validate Onclarity (Becton Dickinson Diagnostics, Sparks, MD), a nine-channel HPV test recently approved by the FDA, by assessing (i) the association of Onclarity types/channels with precancer/cancer; (ii) HPV type/channel agreement between the results of Onclarity and cobas (Roche Molecular Systems, Pleasanton, CA), another FDA-approved test; and (iii) Onclarity typing for all types/channels compared to typing results from a research assay (linear array [LA]; Roche). We compared Onclarity to histopathology, cobas, and LA. We tested a stratified random sample ( n = 9,701) of discarded routine clinical specimens that had tested positive by Hybrid Capture 2 (HC2; Qiagen, Germantown, MD). A subset had already been tested by cobas and LA ( n = 1,965). Cervical histopathology was ascertained from electronic health records. Hierarchical Onclarity channels showed a significant linear association with histological severity. Onclarity and cobas had excellent agreement on partial typing of HPV16, HPV18, and the other 12 types as a pool (sample-weighted kappa value of 0.83); cobas was slightly more sensitive for HPV18 and slightly less sensitive for the pooled high-risk types. Typing by Onclarity showed excellent agreement with types and groups of types identified by LA (kappa values from 0.80 for HPV39/68/35 to 0.97 for HPV16). Onclarity typing results corresponded well to histopathology and to an already validated HPV DNA test and could provide additional clinical typing if such discrimination is determined to be clinically desirable.
- Published
- 2017
10. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study
- Author
-
Hormuzd A. Katki, Nicolas Wentzensen, Philip E. Castle, Walter Kinney, Xiaonan Xue, Barbara Fetterman, Thomas Lorey, Mark A. Schiffman, Julia C. Gage, Fang-Hui Zhao, Nancy Poitras, and Li C. Cheung
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Adenocarcinoma ,California ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Cytology ,Cancer screening ,Internal Medicine ,medicine ,Humans ,Mass Screening ,030212 general & internal medicine ,Papillomaviridae ,Gynecology ,Colposcopy ,Cervical cancer ,Cancer prevention ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,virus diseases ,General Medicine ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,030220 oncology & carcinogenesis ,Observational study ,Female ,Neoplasm Grading ,business ,Carcinoma in Situ ,Cohort study ,Papanicolaou Test - Abstract
Current U.S. cervical cancer screening and management guidelines do not consider previous screening history, because data on multiple-round human papillomavirus (HPV) and cytology "co-testing" have been unavailable.To measure cervical cancer risk in routine practice after successive negative screening co-tests at 3-year intervals.Observational cohort study.Integrated health care system (Kaiser Permanente Northern California, Oakland, California).990 013 women who had 1 or more co-tests from 2003 to 2014.3- and 5-year cumulative detection of (risk for) cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ, and cervical cancer (≥CIN3) in women with different numbers of negative co-tests, overall and within subgroups defined by previous co-test results or baseline age.Five-year ≥CIN3 risks decreased after each successive negative co-test screening round (0.098%, 0.052%, and 0.035%). Five-year ≥CIN3 risks for an HPV-negative co-test, regardless of the cytology result, nearly matched the performance (reassurance) of a negative co-test for each successive round of screening (0.114%, 0.061%, and 0.041%). By comparison, ≥CIN3 risks for the cytology-negative co-test, regardless of the HPV result, also decreased with each successive round, but 3-year risks were as high as 5-year risks after an HPV-negative co-test (0.199%, 0.065%, and 0.043%). No interval cervical cancer cases were diagnosed after the second negative co-test. Independently, ≥CIN3 risks decreased with age. Length of previous screening interval did not influence future ≥CIN3 risks.Interval-censored observational data.After 1 or more negative cervical co-tests (or HPV tests), longer screening intervals (every 5 years or more) might be feasible and safe.National Cancer Institute Intramural Research Program.
- Published
- 2017
11. Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women
- Author
-
Mark Schiffman, Barbara Fetterman, Tina Raine-Bennett, Jessica Lam, Nicolas Wentzensen, Christopher C. Sollecito, Philip E. Castle, Thomas Lorey, Ana Gradissimo, Megan A. Clarke, Robert D. Burk, and Nancy Poitras
- Subjects
0301 basic medicine ,Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Genotype ,Bisulfite sequencing ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Article ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Cytology ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Papillomaviridae ,Aged ,business.industry ,Papillomavirus Infections ,HPV infection ,Cancer ,Computational Biology ,Methylation ,DNA Methylation ,Middle Aged ,medicine.disease ,030104 developmental biology ,CpG site ,ROC Curve ,030220 oncology & carcinogenesis ,Case-Control Studies ,DNA methylation ,DNA, Viral ,CpG Islands ,Female ,business ,Precancerous Conditions - Abstract
Purpose: Human papillomavirus (HPV) DNA methylation testing is a promising triage option for women testing HPV positive during cervical cancer screening. However, the extent to which methylation indicates precancer for all 12 carcinogenic HPV types has not been evaluated. Experimental Design: In this nested case–control study, we tested up to 30 cases of precancer [cervical intraepithelial neoplasia grade 3 (CIN3)/adenocarcinoma in situ (AIS)] and 30 normal controls for each carcinogenic type (single infections with 16/18/31/33/35/39/45/51/52/56/58/59). Next-generation bisulfite sequencing was performed on CpG sites within the L1 and L2 genes. We calculated differences in methylation, ORs, and AUC. Using a fixed sensitivity of 80%, we evaluated the specificity and the risk of CIN3/AIS for best performing CpG sites, and compared the performance of an explorative multi-type methylation assay with current triage strategies. Results: Methylation was positively associated with CIN3/AIS across all 12 types. AUCs for the top sites ranged from 0.71 (HPV51 and HPV56) to 0.86 (HPV18). A combined 12-type methylation assay had the highest Youden index (0.46), compared with cytology (0.31) and a 5-type methylation assay, including only previously described types (0.26). The 12-type methylation assay had higher sensitivity (80% vs. 76.6%) and lower test positivity compared with cytology (38.5% vs. 48.7%). The risk of CIN3/AIS was highest for methylation positives and lowest for cytology or HPV16/18 positives. Conclusions: HPV DNA methylation is a general phenomenon marking the transition from HPV infection to precancer for all 12 carcinogenic types. Development of a combined multitype methylation assay may serve as a triage test for HPV-positive women. Clin Cancer Res; 24(9); 2194–202. ©2018 AACR.
- Published
- 2017
12. Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years
- Author
-
Walter Kinney, Mark Schiffman, Barbara Fetterman, Julia C. Gage, Philip E. Castle, Nancy E. Poitras, Li C. Cheung, Michelle I. Silver, Thomas Lorey, Hormuzd A. Katki, and Alexander Locke
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Conservative management ,Uterine Cervical Neoplasms ,Conservative Treatment ,Lesion ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Postoperative Complications ,Cervical intraepithelial neoplasia grade 2 ,Cytology ,medicine ,Humans ,Young adult ,Retrospective Studies ,Colposcopy ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Cancer ,Retrospective cohort study ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,Neoplasm Grading ,business ,Follow-Up Studies - Abstract
Cervical intraepithelial neoplasia grade 2 (CIN2) frequently regresses, is typically slow-growing, and rarely progresses to cancer. Some women forgo immediate treatment, opting for conservative management (heightened surveillance with cytology and colposcopy), to minimize overtreatment and increased risk of obstetric complications; however, there are limited data examining clinical outcomes in these women. We performed a retrospective cohort analysis of younger women diagnosed with initially untreated CIN1/2, CIN2 and CIN2/3 lesions at Kaiser Permanente Northern California between 2003 and 2015. Clinical outcomes were categorized into five mutually exclusive hierarchical groups: cancer, treated, returned to routine screening, persistent high-grade lesion, or persistent low-grade lesion. Median follow-up for the 2,417 women was 48 months. Six women were diagnosed with cancer (0.2%), all with history of high-grade cytology, and none after a negative cotest. Thirty percent of women were treated, and only 20% returned to routine screening; 50% remained in continued intensive follow-up, of which 86% had either low-grade cytology/histology or high-risk human papillomavirus (HPV) positivity, but not necessarily persistence of a single HPV type. No cancers were detected after a single negative cotest in follow-up. Almost half of initially untreated women did not undergo treatment, but remained by protocol in colposcopy clinic for 2 or more years in the absence of persisting CIN2+. Their incomplete return to total negativity was possibly due to sequential new and unrelated low-grade abnormalities. The prolonged colposcopic surveillance currently required to return to routine screening in the absence of persisting CIN2+ might not be necessary after a negative cotest. Significance: Many younger women under conservative management following an initial CIN2 result remain in a clinical protocol of prolonged intensified surveillance without a subsequent diagnosis of CIN2 or more severe diagnoses. More research is needed to determine whether such prolonged management might be unnecessary following a negative cotest for those women with an initial CIN2 but otherwise only low-grade findings. Cancer Prev Res; 11(3); 165–70. ©2018 AACR.
- Published
- 2017
13. Why does cervical cancer occur in a state-of-the-art screening program?
- Author
-
Philip E. Castle, Julia C. Gage, Hormuzd A. Katki, Mark Schiffman, Barbara Fetterman, John Schussler, Walter Kinney, Thomas Lorey, Li C. Cheung, Nicolas Wentzensen, Nancy Poitras, and Brian Befano
- Subjects
Adult ,medicine.medical_specialty ,Cytodiagnosis ,Uterine Cervical Neoplasms ,Adenocarcinoma ,Cervical cancer screening ,Article ,Causes of cancer ,03 medical and health sciences ,0302 clinical medicine ,Cytology ,medicine ,Humans ,030212 general & internal medicine ,Treatment Failure ,Stage (cooking) ,False Negative Reactions ,Papillomaviridae ,Early Detection of Cancer ,Cervical cancer ,Gynecology ,Cervical screening ,business.industry ,Obstetrics ,Age Factors ,Obstetrics and Gynecology ,Cancer ,Sampling error ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Patient Compliance ,Female ,business ,Precancerous Conditions - Abstract
The goal of cervical screening is to detect and treat precancers before some become cancer. We wanted to understand why, despite state-of-the-art methods, cervical cancers occured in relationship to programmatic performance at Kaiser Permanente Northern California (KPNC), where1,000,000 women aged ≥30years have undergone cervical cancer screening by triennial HPV and cytology cotesting since 2003.We reviewed clinical histories preceding cervical cancer diagnoses to assign "causes" of cancer. We calculated surrogate measures of programmatic effectiveness (precancers/(precancers and cancers)) and diagnostic yield (precancers and cancers per 1000 cotests), overall and by age at cotest (30-39, 40-49, and ≥50years).Cancer was rare and found mainly in a localized (treatable) stage. Of 623 cervical cancers with at least one preceding or concurrent cotest, 360 (57.8%) were judged to be prevalent (diagnosed at a localized stage within one year or regional/distant stage within two years of the first cotest). Non-compliance with recommended screening and management preceded 9.0% of all cancers. False-negative cotests/sampling errors (HPV and cytology negative), false-negative histologic diagnoses, and treatment failures preceded 11.2%, 9.0%, and 4.3%, respectively, of all cancers. There was significant heterogeneity in the causes of cancer by histologic category (p0.001 for all; p=0.002 excluding prevalent cases). Programmatic effectiveness (95.3%) and diagnostic yield were greater for squamous cell versus adenocarcinoma histology (p0.0001) and both decreased with older ages (pA state-of-the-art intensive screening program results in very few cervical cancers, most of which are detected early by screening. Screening may become less efficient at older ages.
- Published
- 2017
14. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
- Author
-
Barbara Fetterman, Julia C. Gage, Joël Fokom Domgue, Thomas Lorey, Tina Raine-Bennett, Nancy E. Poitras, Mark Schiffman, Lais S. Miachon, Michael Dean, Philip E. Castle, Yi Xie, Brian Befano, and Nicolas Wentzensen
- Subjects
Microbiology (medical) ,Oncology ,Adult ,medicine.medical_specialty ,Epidemiology ,Uterine Cervical Neoplasms ,Real-Time Polymerase Chain Reaction ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,Virology ,medicine ,Humans ,030212 general & internal medicine ,Human papillomavirus ,Papillomaviridae ,Early Detection of Cancer ,Aged ,Cervical cancer ,Cervical screening ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,United States ,Hpv testing ,Real-time polymerase chain reaction ,Molecular Diagnostic Techniques ,030220 oncology & carcinogenesis ,Costs and Cost Analysis ,Lower cost ,Female ,business ,Limited resources - Abstract
Inexpensive and easy-to-perform human papillomavirus (HPV) tests are needed for primary cervical cancer screening in lower-resource regions. In a convenience sample of 516 residual exfoliative cervical specimens from the Kaiser Permanente Northern California and U.S. National Cancer Institute Persistence and Progression Study, we assessed the agreement and clinical performance of a simple, inexpensive real-time PCR assay for the detection of 13 carcinogenic HPV types (the H13 assay; Hybribio, Hong Kong) that is marketed in limited-resource settings compared to previous testing by the Hybrid Capture 2 assay (HC2; Qiagen, Germantown, MD) and the Onclarity assay (BD Diagnostics, Sparks, MD). The test set was chosen to include many HPV-positive specimens. The reference standard was a combination of HC2 and Onclarity results for HPV detection and histologic diagnosis of controls (less than cervical intraepithelial neoplasia grade 2 [P < 0.001) and P < 0.001). In conclusion, H13 corresponds well to the combination of HC2 and Onclarity and has good clinical accuracy compared to histologic diagnosis, with less cross-reactivity with untargeted HPV types than HC2. H13 is a lower-cost HPV DNA test that might be useful for primary screening in limited-resource settings.
- Published
- 2017
15. Cervical Cancer Rates After the Transition From Annual Pap to 3-Year HPV and Pap
- Author
-
Barbara Fetterman, Philip E. Castle, Thomas Lorey, Helen E. Dinkelspiel, Nancy Poitras, J. Thomas Cox, and Walter Kinney
- Subjects
Adult ,medicine.medical_specialty ,Time Factors ,Uterine Cervical Neoplasms ,Cervical cancer screening ,California ,Human Papillomavirus DNA Tests ,medicine ,Human papillomavirus DNA ,Humans ,Pap test ,Papillomaviridae ,Early Detection of Cancer ,Cervical cancer ,Invasive carcinoma ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,medicine.disease ,Cancer registry ,Hpv testing ,Female ,business ,Cervical cancer incidence ,Papanicolaou Test - Abstract
OBJECTIVE Kaiser Permanente Northern California (KPNC) introduced 3-year Pap and human papillomavirus DNA cotesting for cervical cancer screening in women 30 years or older in 2003 to 2004. Patient and provider willingness to extend screening intervals and the impact on annual cervical cancer incidence after interval extension are evaluated. MATERIALS AND METHODS Age-adjusted cervical cancer rates and screening intervals were calculated from KPNC Regional Laboratory databases and Northern California Cancer Registry from 2000 to 2009. RESULTS The median screening interval between negative cotests was 36 months compared to the 16 months after a negative Pap test alone before the implementation of cotesting. The age-adjusted invasive cancer rate was 6.5 per 100,000 women in 2000 and 6.3 in 2009; there was no difference in the rates of cervical cancer in women 30 years or older from 2000 to 2009 (p(trend) = .7). CONCLUSIONS Patients and providers were compliant with the extension of screening intervals with cotesting. Cervical cancer rates remained constant during the 10-year study period despite extending screening intervals after a negative cotest.
- Published
- 2014
16. Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results
- Author
-
Julia C. Gage, Hormuzd A. Katki, Walter Kinney, Li C. Cheung, Tina Raine-Bennett, Nancy Poitras, Thomas Lorey, Mark Schiffman, Barbara Fetterman, and Philip E. Castle
- Subjects
Adult ,medicine.medical_specialty ,MEDLINE ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Risk Assessment ,Article ,Cohort Studies ,Virology ,medicine ,Humans ,Mass Screening ,Mass screening ,Vaginal Smears ,Cervical cancer ,Gynecology ,business.industry ,Obstetrics ,Papillomavirus Infections ,Clinical performance ,virus diseases ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,Uterine Cervical Dysplasia ,medicine.disease ,female genital diseases and pregnancy complications ,Hpv testing ,Female ,Risk assessment ,business ,Cohort study - Abstract
New screening guidelines recommend that human papillomavirus (HPV)-negative/atypical squamous cells of undetermined significance (ASC-US) results be considered as equivalent to HPV-negative/Pap-negative results, leading to rescreening in 5 years. However, despite ample data, the routine clinical performance of HPV testing of women with ASC-US has not been adequately documented.We estimated 5-year risks of cervical intraepithelial neoplasia (CIN) 3+ and of cancer among 2 groups of women between 2003 and 2010 at Kaiser Permanente Northern California: 27,050 aged 30 to 64 years who underwent HPV and Pap cotesting and had an ASC-US Pap result and 12,209 aged 25 to 29 years who underwent HPV triage of ASC-US.Five-year risks of CIN 3+ and of cancer among women aged 30 to 64 years testing HPV-negative/ASC-US and among 923,152 women testing Pap-negative alone were similar although statistically distinguishable (CIN 3+, 0.43% vs 0.26%, p = .001; cancer, 0.050% vs 0.025%, p = .1). The increased risk of cancer after HPV-negative/ASC-US versus Pap-negative alone was confined to women aged 60 to 64 years (0.26% vs 0.035%, p = .3). Five-year risks of CIN 3+ and cancer among women with HPV-negative/ASC-US results were substantially higher than those among women testing HPV-negative/Pap-negative (CIN 3+, 0.43% vs 0.08%, p.0001; cancer, 0.050% vs 0.011%, p = .003). For women aged 30 to 64 years testing HPV-positive/ASC-US, 5-year risks of CIN 3+ and cancer were slightly higher than those among 9,374 women with low-grade squamous intraepithelial lesion (LSIL) (CIN 3+, 6.8% vs 5.2%, p = .0007; cancer, 0.41% vs 0.16%, p = .04). Similar patterns were seen for women aged 25 to 29 years.Women with HPV-negative/ASC-US had a similar risk as women testing Pap-negative alone but had a higher risk than women testing HPV-negative/Pap-negative. Based upon the principle of "equal management of equal risks," our findings support the equal management of women with HPV-negative/ASC-US and those with Pap-negative alone, except for exiting women from screening because cancer risks at ages 60 to 64 years may be higher for women testing HPV-negative/ASC-US. Our findings also support managing HPV-positive/ASC-US and LSIL similarly.
- Published
- 2013
17. Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive
- Author
-
Mark Schiffman, Barbara Fetterman, Li C. Cheung, Walter Kinney, Philip E. Castle, Hormuzd A. Katki, Julia C. Gage, Nancy Poitras, Tina Raine-Bennett, and Thomas Lorey
- Subjects
Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Risk Assessment ,Article ,California ,Cohort Studies ,Virology ,medicine ,Humans ,Mass Screening ,Prospective cohort study ,Mass screening ,Vaginal Smears ,Gynecology ,Colposcopy ,Cervical cancer ,Cancer prevention ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,Uterine Cervical Dysplasia ,medicine.disease ,female genital diseases and pregnancy complications ,Female ,business ,Risk assessment ,Cohort study - Abstract
Current US guidelines for cotesting recommend that the large numbers of women who test Pap-negative, but human papillomavirus (HPV)-positive, return in 1 year, and those who remain HPV-positive or have low-grade squamous intraepithelial lesion (LSIL) or worse Pap results be referred for colposcopy. However, the performance of these guidelines in routine clinical practice has not been evaluated.We estimated cumulative 5-year risks of cervical intraepithelial neoplasia grade 3 or worse (CIN 3+) among 32,374 women aged 30 to 64 years with HPV-positive/Pap-negative cotest results at Kaiser Permanente Northern California during 2003 to 2010.The 5-year CIN 3+ risk after an HPV-positive/Pap-negative cotest result, which was found in 3.6% of women, was 4.5% (95% confidence interval [CI] = 4.2%-4.8%). The 5-year cancer risk was 0.34% (95% CI = 0.26%-0.45%), and half of the cases were adenocarcinoma. Overall, 48% of the women remained HPV-positive on return (median = 418 days after baseline), a percentage that varied little over ages 30 to 64 years. At the return after a baseline HPV-positive/Pap-negative result, almost every repeat cotest result predicted greater subsequent 5-year CIN 3+ risk than the same cotest result had at baseline (HPV-positive/LSIL, 9.2% vs 6.1%, p = .01; HPV-positive/atypical squamous cells of undetermined significance [ASC-US], 7.9% vs 6.8%, p = .2; HPV-positive/Pap-negative, 7.4% vs 4.5%, p.0001; HPV-negative/LSIL,1.7% vs 2.0%, p = .8; HPV-negative/ASC-US, 2.9% vs 0.43%, p = .0005; HPV-negative/Pap-negative, 0.93% vs 0.08%, p.0001).Using the principle of "equal management of equal risks," women testing HPV-positive/Pap-negative had a subsequent CIN 3+ risk consistent with risk thresholds for a 1-year return. However, on returning in approximately 1 year, about one-half of women will be referred for colposcopy because of continued HPV positivity or Pap abnormality. Clinicians should keep in mind that cotest results at the return after a baseline HPV-positive/Pap-negative finding are riskier than the same baseline cotest results in the general population, supporting intensified clinical management at return testing.
- Published
- 2013
18. Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years
- Author
-
Julia C. Gage, Mark Schiffman, Barbara Fetterman, Walter Kinney, Philip E. Castle, Thomas Lorey, Li C. Cheung, Tina Raine-Bennett, Nancy Poitras, and Hormuzd A. Katki
- Subjects
Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Risk Assessment ,California ,Article ,Cohort Studies ,Young Adult ,Virology ,medicine ,Humans ,Mass Screening ,Pap test ,Young adult ,Mass screening ,Vaginal Smears ,Gynecology ,Cancer prevention ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,General Medicine ,Uterine Cervical Dysplasia ,medicine.disease ,Squamous intraepithelial lesion ,Female ,business ,Risk assessment ,Cohort study - Abstract
OBJECTIVE Current US national guidelines recommend beginning screening at age 21 using Pap tests only, with cotesting starting at age 30. To inform the management of Pap test abnormalities among women aged 21 to 24 years, who have extremely low cancer risks, we compared risks of CIN 3+ among women aged 21 to 24 versus 25 to 29 years or 30 to 64 years. METHODS We estimated 5-year risks of CIN 3+ given different Pap test results, with human papillomavirus (HPV) triage of atypical squamous cells of undetermined significance (ASC-US), among 133,947 women aged 21 to 24 years, compared with 135,382 women aged 25 to 29 years and 965,360 women aged 30 to 64 years, between 2003 and 2010 at Kaiser Permanente Northern California. RESULTS There were 3 cancers diagnosed during follow-up in women aged 21 to 24 years. After high-grade Pap results (0.6% of Pap results), the 5-year CIN 3+ risks among women aged 21 to 24 years were comparable to those aged 25 to 29 and 30 to 64 years (atypical glandular cells, 6.9% vs 14% vs 8.5%, p = .8; atypical squamous cells cannot rule out high-grade squamous intraepithelial lesion, 16% vs 24% vs 18%, p = .8; high-grade squamous intraepithelial lesion, 28% vs 28% vs 47%, p = .4). After low-grade squamous intraepithelial lesion, the 5-year CIN 3+ risk was lower among women aged 21 to 24 years (3.0%) than that among women aged 25 to 29 years (5.0%, p = .01) or aged 30 to 64 years (5.2%, p = .0002). Although the 5-year CIN 3+ risk after HPV-negative/ASC-US was similar across all 3 groups (0.57% vs 0.59% vs 0.43%, p = 1), risk after HPV-positive/ASC-US was lower among women aged 21 to 24 years (4.4%) than that among women aged 25 to 29 years (7.1%, p < .0001) or 30 to 64 years (6.8%, p < .0001). CONCLUSIONS Women aged 21 to 24 years had almost zero cancer risk, and positive Pap test results predicted low CIN 3+ risk except for the 0.6% of women with high-grade Pap results. The generally low risk supports conservative management of women aged 21 to 24 years.
- Published
- 2013
19. Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results
- Author
-
Walter Kinney, Mark Schiffman, Barbara Fetterman, Li C. Cheung, Tina Raine-Bennett, Philip E. Castle, Hormuzd A. Katki, Thomas Lorey, Nancy Poitras, and Julia C. Gage
- Subjects
Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Risk Assessment ,Article ,Cohort Studies ,Virology ,HPV Negative ,Humans ,Mass Screening ,Medicine ,Mass screening ,Vaginal Smears ,Gynecology ,business.industry ,Obstetrics ,HPV Positive ,Papillomavirus Infections ,virus diseases ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,Uterine Cervical Dysplasia ,medicine.disease ,Triage ,United States ,female genital diseases and pregnancy complications ,Hpv testing ,Female ,business ,Risk assessment ,Cohort study - Abstract
Low-grade squamous intraepithelial lesion (LSIL) Pap results do not typically lead to human papillomavirus (HPV) testing. HPV triage is not cost-effective because most cases are HPV-positive. However, under new national guidelines recommending cotesting for women aged 30 to 64 years, clinicians will increasingly receive the HPV test result with LSIL Pap results. Some authors have suggested that HPV triage might be effective at older ages, when the percentage of HPV positivity among women with LSIL declines.We estimated 5-year risks of CIN 2+ and CIN 3+ among 9,033 women aged 30 to 64 years who had both an HPV test and an LSIL Pap result.HPV positivity among women with LSIL decreased only slightly with age (30 to 34 vs 60 to 64 years, 88% vs 72%, p.0001). The 5-year risks of CIN 2+ and CIN 3+ of women aged 30 to 64 years testing HPV-positive/LSIL were larger than those among women testing HPV-negative/LSIL (CIN 2+, 19% vs 5.1%, p.0001; CIN 3+, 6.1% vs 2.0%, p.0001). The 5-year risk of CIN 3+ in HPV-negative/LSIL women was similar to that for women with atypical squamous cells of undetermined significance (ASC-US) Pap test result without knowledge of HPV test results (2.0% vs 2.6%, p = .4).HPV-negative/LSIL posed lower risk than other Pap results that guidelines currently recommend for referral to immediate colposcopy. By the principle of "equal management of equal risks," women with HPV-negative/LSIL might reasonably be managed similarly to those with ASC-US Pap results without knowledge of HPV testing, that is, retesting at 6 to 12 months, rather than immediate colposcopy. Although the HPV test result for LSIL Pap results provides actionable information to clinicians who screen with cotesting, the high HPV positivity of LSIL at even the oldest ages suggests the lack of cost-effectiveness of HPV triage of LSIL for clinicians who do not use routine cotesting.
- Published
- 2013
20. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact
- Author
-
Allison L. Naleway, Roger Baxter, Karen Riedlinger, Lauri E. Markowitz, Nicola P. Klein, Elizabeth R. Unger, Eileen F. Dunne, Martin Steinau, Sheila Weinmann, Mariela Z. Scarbrough, Barbara Fetterman, and Julianne Gee
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Uterine Cervical Neoplasms ,Alphapapillomavirus ,California ,Young Adult ,Papillomavirus Vaccines ,Healthcare delivery ,Risk Factors ,Internal medicine ,Epidemiology ,Genotype ,Prevalence ,medicine ,Humans ,Young adult ,Child ,Early Detection of Cancer ,Gynecology ,Cervical cancer ,Hpv types ,Delivery of Health Care, Integrated ,business.industry ,Papillomavirus Infections ,virus diseases ,medicine.disease ,Oncology ,Specimen collection ,Female ,business - Abstract
Two human papillomavirus (HPV) vaccines are available to prevent cervical cancer. One early measure of HPV vaccine impact would be a reduction in vaccine-related HPV types (HPV 6, 11, 16, or 18, or HPV 16, 18) in cervical samples from young women. We aimed to assess feasibility of specimen collection and baseline HPV prevalence in an integrated healthcare delivery system. Residual cervical specimens collected during routine cervical cancer screening (2006–2008) were retained consecutively from eligible females aged 11–29 years, stratified by age group. Specimens were evaluated for 37 HPV genotypes using the Roche Linear Array assay. Of 10,124 specimens submitted, 10,103 (99 %) were adequate for HPV testing. Prevalence of HPV 6, 11, 16, or 18 genotype was 11.4 % overall and was the highest in the youngest age group (18.1 % in the 11–19-year-olds, 12.5 % in the 20–24-year-olds, and 7.0 % in the 25–29-year-olds). HPV types 6, 11, 16, or 18 prevalence could be measured over time to assess early HPV vaccine impact using residual specimens from an integrated healthcare delivery system, particularly if sampling focused on young women.
- Published
- 2013
21. A cohort study of cervical screening using partial HPV typing and cytology triage
- Author
-
Mark, Schiffman, Noorie, Hyun, Tina R, Raine-Bennett, Hormuzd, Katki, Barbara, Fetterman, Julia C, Gage, Li C, Cheung, Brian, Befano, Nancy, Poitras, Thomas, Lorey, Philip E, Castle, and Nicolas, Wentzensen
- Subjects
Adult ,Cohort Studies ,Vaginal Smears ,Human papillomavirus 16 ,Papillomavirus Infections ,Humans ,Uterine Cervical Neoplasms ,Female ,Middle Aged ,Triage ,Uterine Cervical Dysplasia ,Papillomaviridae ,Aged - Abstract
HPV testing is more sensitive than cytology for cervical screening. However, to incorporate HPV tests into screening, risk-stratification ("triage") of HPV-positive women is needed to avoid excessive colposcopy and overtreatment. We prospectively evaluated combinations of partial HPV typing (Onclarity, BD) and cytology triage, and explored whether management could be simplified, based on grouping combinations yielding similar 3-year or 18-month CIN3+ risks. We typed ∼9,000 archived specimens, taken at enrollment (2007-2011) into the NCI-Kaiser Permanente Northern California (KPNC) HPV Persistence and Progression (PaP) cohort. Stratified sampling, with reweighting in the statistical analysis, permitted risk estimation of HPV/cytology combinations for the 700,000+-woman KPNC screening population. Based on 3-year CIN3+ risks, Onclarity results could be combined into five groups (HPV16, else HPV18/45, else HPV31/33/58/52, else HPV51/35/39/68/56/66/68, else HPV negative); cytology results fell into three risk groups ("high-grade," ASC-US/LSIL, NILM). For the resultant 15 HPV group-cytology combinations, 3-year CIN3+ risks ranged 1,000-fold from 60.6% to 0.06%. To guide management, we compared the risks to established "benchmark" risk/management thresholds in this same population (e.g., LSIL predicted 3-year CIN3+ risk of 5.8% in the screening population, providing the benchmark for colposcopic referral). By benchmarking to 3-year risk thresholds (supplemented by 18-month estimates), the widely varying risk strata could be condensed into four action bands (very high risk of CIN3+ mandating consideration of cone biopsy if colposcopy did not find precancer; moderate risk justifying colposcopy; low risk managed by intensified follow-up to permit HPV "clearance"; and very low risk permitting routine screening.) Overall, the results support primary HPV testing, with management of HPV-positive women using partial HPV typing and cytology.
- Published
- 2016
22. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen
- Author
-
Michelle I, Silver, Mark, Schiffman, Barbara, Fetterman, Nancy E, Poitras, Julia C, Gage, Nicolas, Wentzensen, Thomas, Lorey, Walter K, Kinney, and Philip E, Castle
- Subjects
Adult ,Vaginal Smears ,Papillomavirus Infections ,Uterine Cervical Neoplasms ,Middle Aged ,Uterine Cervical Dysplasia ,California ,Article ,Colposcopy ,Risk Factors ,Humans ,Mass Screening ,Female ,Papillomaviridae ,Precancerous Conditions ,Risk Reduction Behavior ,Papanicolaou Test - Abstract
The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3-year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered.Two cohorts were defined. The "open cohort" included all women screened at least once during the study period; 1 million cotests were performed. In a fixed "long-term screening cohort," the authors considered the cumulative impact of repeated screening at 3-year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group).Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004-2006: 82.0/100,000 women screened; 2007-2009: 140.6/100,000 women screened; and 2010-2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long-term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004-2006: 80.5/100,000 women screened; 2007-2009: 118.6/100,000 women screened; and 2010-2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening.Repeated cotesting at a 3-year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682-6. © 2016 American Cancer Society.
- Published
- 2016
23. Screening history preceding a diagnosis of cervical cancer in women age 65 and older
- Author
-
Nancy Poitras, Thomas Lorey, Barbara Fetterman, Philip E. Castle, J. Thomas Cox, Walter Kinney, and Helen E. Dinkelspiel
- Subjects
Aged, 80 and over ,Cervical cancer ,Gynecology ,medicine.medical_specialty ,Pap smears ,Invasive carcinoma ,Obstetrics ,business.industry ,Uterine Cervical Neoplasms ,Obstetrics and Gynecology ,medicine.disease ,Oncology ,Age groups ,Risk Factors ,Regional cancer ,medicine ,Humans ,Mass Screening ,Female ,Hpv test ,business ,Aged - Abstract
Objective To characterize the antecedent screening of women 65years of age and older diagnosed with cervical cancer. Methods Screening histories of women 65years of age and older who were diagnosed with cervical cancer between 2003 and 2008 were examined utilizing the organization's databases and the regional Cancer Registry. Stopping screening was recommended at age 65 for members who had either 3 consecutive negative Paps or a single negative Pap plus HPV test ("cotest"). Results From 2003 through 2008 there were 56 Kaiser Permanente Northern California members 65years of age and older diagnosed with cervical cancer. During the same time period there were 1,323,100 woman-years of membership in women age 65 and older. The risk of invasive cancer among women age 65 and older was 4.2/100,000/year in 2003–2008. 33 of 56 (59%) had one or more Pap smears prior to diagnosis. Of the 33, 14 women (25%) had 3 consecutive negative Pap smears prior to diagnosis. Three of 46,401 women with 1 or more negative cotests at age 65 and older were subsequently diagnosed with invasive cancer during 132,639 women-years of follow-up (2.3/100,000/year). Conclusions Most cervical cancers diagnosed at age 65 and older occur in women who have not met our criteria for stopping screening. A few cancers will continue to occur at age 65 and older despite multiple negative tests, as is true in other age groups. We currently have no evidence that these cancers would be prevented with continued screening at ages 65 and older.
- Published
- 2012
24. Comparison of the cobas Human Papillomavirus (HPV) Test with the Hybrid Capture 2 and Linear Array HPV DNA Tests
- Author
-
Carrie Aldrich, Brandon LaMere, Thomas Lorey, Walter Kinney, Mark Schiffman, Barbara Fetterman, Philip E. Castle, Julia C. Gage, Mark Sadorra, and Randi Kail
- Subjects
Adult ,Microbiology (medical) ,Biology ,Linear array ,Virology ,Genotype ,Humans ,Hpv test ,Human papillomavirus ,Papillomaviridae ,Aged ,Aged, 80 and over ,HPV Positive ,Papillomavirus Infections ,Hybrid capture ,virus diseases ,Middle Aged ,biology.organism_classification ,United States ,female genital diseases and pregnancy complications ,Hpv testing ,Molecular Diagnostic Techniques ,DNA, Viral ,Female - Abstract
The cobas human papillomavirus (HPV) test (cobas) was recently approved by the U.S. Food and Drug Administration (FDA) and identifies HPV16 and HPV18 separately as well as detecting a pool of 11 HR-HPV genotypes (HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -68) and also HPV66. We compared cobas, Linear Array (LA), and Hybrid Capture 2 (HC2) assays for detection of carcinogenic HPV DNA, and cobas and LA for detection of HPV16 and HPV18 DNA, among the first 1,852 women enrolled in the HPV Persistence and Progression Cohort (PaP Cohort) study. Specimens were tested by all 3 assays 1 year after an HC2-positive result. In 1,824 specimens with cobas results, cobas had an 85.9% agreement with HC2 and 91.0% agreement with LA for carcinogenic HPV detection. When results between cobas and HC2 disagreed, cobas tended to call more women HPV positive ( P < 0.01). Categorizing cobas and LA results hierarchically according to cancer risk (HPV16, HPV18, other carcinogenic HPV genotypes, or carcinogen negative), there was a 90% agreement for all categories of HPV ( n = 1,824). We found good agreement between the two U.S. FDA-approved HPV tests, with discrepancies between the two assays due to specific characteristics of the individual assays. Additional studies are needed to compare HC2 and cobas for detecting and predicting CIN3 to understand the clinical implications of the discrepant test results between the two tests.
- Published
- 2012
25. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice
- Author
-
Thomas Lorey, J. Thomas Cox, Walter Kinney, Tracy Flanagan, Barbara Fetterman, and Philip E. Castle
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Article ,Internal medicine ,medicine ,Humans ,Neoplasm Invasiveness ,Routine clinical practice ,Human papillomavirus ,Papillomaviridae ,Neoplasm Staging ,Cervical cancer ,business.industry ,Papillomavirus Infections ,virus diseases ,Obstetrics and Gynecology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,female genital diseases and pregnancy complications ,Hpv testing ,High risk hpv ,Female ,business - Abstract
To characterize the cervical cancers diagnosed following a Pap-negative, high risk human papillomavirus (HPV)-positive (Pap-/HPV+) screen in routine clinical practice.Using data from Kaiser Permanente Northern California, we investigated the cases of cervical cancer diagnosed between January, 2003 and January, 2009 following Pap-/HPV+ screen. Two cervical specimens were routinely collected for cervical cancer screening, one for conventional cytology and the other for high risk HPV testing using Hybrid Capture 2 (Qiagen).Forty-four women (median age at diagnosis=44years) were diagnosed with primary invasive cervical cancer with a recent history of one or more Pap-/HPV+ screens. Twenty-six women had one Pap-/HPV+ screen preceding the diagnosis of cancer, 15 had two, and three had three. There were 16 squamous cancers, one small cell cancer, 24 adenocarcinomas, 2 adenosquamous carcinomas, and one case with separate invasive squamous and adenocarcinoma. FIGO Stage was IA in 11 women, IB in 31 women and IIA in 2 women. Treatment included a pelvic node dissection in 30, 2 (6.7%) of whom had positive nodes.HPV testing contributes to early cervical cancer diagnosis detection in women with negative Pap tests. Most women in this cohort have early stage, node negative, treatable and potentially curable disease. Adenocarcinoma predominated as might be expected because cytology misses these cancers and their precursors. The majority of cancers were diagnosed following a single Pap-/HPV+ screen, suggesting that effective triage to colposcopy of women with a Pap-/HPV+ screen would be preferable to retesting in one year as currently recommended.
- Published
- 2011
26. Lessons From Practice
- Author
-
Thomas Lorey, Nancy Poitras, Philip E. Castle, Gaea Moore, J. Thomas Cox, Walter Kinney, and Barbara Fetterman
- Subjects
medicine.medical_specialty ,Uterine Cervical Neoplasms ,Atypical Squamous Cells ,Screening Result ,Medical care ,California ,Article ,Young Adult ,Risk Factors ,medicine ,Humans ,Early Detection of Cancer ,Colposcopy ,Gynecology ,medicine.diagnostic_test ,Obstetrics ,business.industry ,HPV Positive ,Papillomavirus Infections ,Obstetrics and Gynecology ,Cancer ,General Medicine ,Uterine Cervical Dysplasia ,medicine.disease ,Squamous intraepithelial lesion ,Cervical intraepithelial neoplasia 3 ,Female ,business - Abstract
Objective. To characterize the risks of cervical intraepithelial neoplasia 3 (CIN 3) and cancer in women aged 21 to 24 with human papillomavirus (HPV)-positive atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) screening results in routine clinical practice. Materials and Methods. Quality assurance databases containing records of screening test and histologic findings from the Regional Laboratory of the Northern California Kaiser Permanente Medical Care Program were reviewed. Numbers of LSIL and HPV-positive ASC-US results and associated cancers and CIN 3 in women aged 21 to 24 during 2003 to 2007 were tabulated, and the corresponding risks were calculated overall and by year of age. Results. During the 5-year period from 2003 to 2007, 1,620 HPV-positive ASC-US and 2,175 LSIL were diagnosed in women aged 21 to 24, for which corresponding histologic finding is available. No invasive cancers were detected in association with LSIL and HPV-positive ASC-US screening results in this age group during this period. The risk of cancer was therefore 0% (95% CI = 0.00%-0.10%). The risk of CIN 3 associated with an HPV-positive ASC-US was 2.90% (95% CI = 2.14%-3.84%), with LSIL was 2.44% (95% CI = 1.83%-3.18%), and, for the 2 combined, the risk was 2.64% (95% CI = 2.15%-3.20%). Conclusions. The risk of CIN 3 and cancer is low enough that management of women aged 21 to 24 with ASC-US and LSIL smears without immediate colposcopy should be considered, as is currently recommended for women aged 20 and younger.
- Published
- 2010
27. Age-appropriate use of human papillomavirus vaccines in the U.S
- Author
-
Israh Akhtar, Richard S. Guido, Philip E. Castle, Michael A. Gold, Barbara Fetterman, Mujtaba Husain, Walter Kinney, and Andrew G. Glass
- Subjects
Oncology ,medicine.medical_specialty ,Population ,Uterine Cervical Neoplasms ,HPV vaccines ,Cervical intraepithelial neoplasia ,Article ,Genital warts ,Uterine Cervical Diseases ,Papillomavirus Vaccines ,Internal medicine ,medicine ,Humans ,education ,Gynecology ,Cervical cancer ,Human papillomavirus 16 ,education.field_of_study ,Human papillomavirus 18 ,business.industry ,Papillomavirus Infections ,Age Factors ,virus diseases ,Obstetrics and Gynecology ,Uterine Cervical Dysplasia ,medicine.disease ,United States ,female genital diseases and pregnancy complications ,Vaccination ,Female ,business - Abstract
Cervical infections by approximately 15 cancer-associated (carcinogenic) human papillomavirus (HPV) genotypes cause virtually all cervical cancer and its immediate precursor lesions worldwide. Prophylactic vaccines against human papillomavirus (HPV) types HPV16 and HP18, which cause 70% of cervical cancer worldwide, hold great promise for reducing the burden of cervical cancer worldwide. However, current HPV vaccines prevent future infections and related cervical abnormalities and do not treat pre-existing HPV infections. In the U.S., HPV vaccine introduction should be considered in the context of a very successful cervical cancer screening program that has reduced the rates of cervical cancer by 75% or more. Thus, HPV vaccines will only prevent an incremental number of additional cervical cancers in the U.S. The introduction of HPV vaccines can also prevent other HPV-related sequelae, most importantly cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3), which precede the development of cervical cancer and require clinical follow-up and treatment. Examining data from 7 clinical centers in the U.S., the median age of CIN2/3 is typically between 25 and 30 years of age in 2007; if screen-detected CIN2/3 develops on average 5-10 years after the causal infection is acquired, HPV vaccination will only prevent a significant proportion of CIN2/3 if it is given to women before the age of 26 and more so if given to women 18 and younger. It is increasingly evident that prophylactic HPV vaccines will provide the greatest public health or population benefit only when delivered to adolescent, mostly HPV-naive women.
- Published
- 2009
28. Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting
- Author
-
Philip E. Castle, Walter Kinney, Thomas Lorey, Nancy Poitras, Barbara Fetterman, and Ruth Shaber
- Subjects
Adult ,medicine.medical_specialty ,Population ,Uterine Cervical Neoplasms ,Papanicolaou stain ,Comorbidity ,Article ,medicine ,Human papillomavirus DNA ,Humans ,Mass Screening ,Papillomaviridae ,Human papillomavirus ,education ,Mass screening ,Aged ,Aged, 80 and over ,Vaginal Smears ,Gynecology ,education.field_of_study ,biology ,business.industry ,Papillomavirus Infections ,virus diseases ,Obstetrics and Gynecology ,Papanicolaou Test ,Middle Aged ,biology.organism_classification ,female genital diseases and pregnancy complications ,Test (assessment) ,DNA, Viral ,Female ,business - Abstract
To estimate the 5-year age group-specific test positives for Pap tests and human papillomavirus (HPV) testing in a large, general screening population of women 30 and older.Using data from Kaiser Permanente Northern California, a large health maintenance organization that introduced cotesting in 2003, we evaluated the cotesting results overall and by 5-year age groups. Women (n=580,289) who opted for and underwent cotesting (n cotests=812,598) between January 2003 and April 2008 were included in the analysis. Pap tests interpreted as atypical squamous cells of undetermined significance (ASC-US) or more severe were considered to be positive. Women were tested for carcinogenic HPV using an assay approved by the U.S. Food and Drug Administration. Binomial exact 95% confidence intervals (CIs) were calculated.Overall, 6.27% (95% CI 6.21-6.32%) of cotests were carcinogenic HPV positive, and only 3.99% (95% CI 3.94-4.03%) cotests had normal cytology and were carcinogenic HPV positive. By comparison, 5.18% (95% CI 5.13-5.23%) of cotests had ASC-US or more severe cytology, and 2.87% (95% CI 2.84-2.91%) of cotests had ASC-US or more severe cytology and were carcinogenic HPV negative.In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out.
- Published
- 2009
29. A Study of HPV Typing for the Management of HPV-Positive ASC-US Cervical Cytologic Results
- Author
-
Nicolas Wentzensen, Hormuzd A. Katki, Julia C. Gage, Laurence M. Vaughan, Philip E. Castle, Brian Befano, Tina Raine-Bennett, Mark Schiffman, and Barbara Fetterman
- Subjects
Adult ,medicine.medical_specialty ,Genotype ,HPV typing ,Uterine Cervical Neoplasms ,Article ,Young Adult ,Cytology ,medicine ,Atypical Squamous Cells of the Cervix ,Humans ,Typing ,Papillomaviridae ,Colposcopy ,Gynecology ,Vaginal Smears ,Cervical screening ,medicine.diagnostic_test ,Obstetrics ,business.industry ,HPV Positive ,Papillomavirus Infections ,Obstetrics and Gynecology ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Hpv testing ,Oncology ,Female ,Squamous Intraepithelial Lesions of the Cervix ,business - Abstract
In US cervical screening, immediate colposcopy is recommended for women with HPV-positive ASC-US (equivocal) cytology. We evaluated whether partial typing by Onclarity™ (BD) might identify HPV-positive women with low enough CIN3+ risk to permit 1-year follow-up instead.The NCI-Kaiser Permanente Northern California Persistence and Progression cohort includes a subset of 13,890 women aged 21+ with HC2 (Qiagen)-positive ASC-US at enrollment; current median follow-up is 3.0years. Using stratified random sampling, we typed 2079 archived enrollment specimens including 329 women subsequently diagnosed with CIN3+, 563 with CIN2, and 1187 withCIN2. Adjusting for sampling, we computed 3-year cumulative CIN3+ risks for each Onclarity typing channel, using Kaplan-Meier methods.The 3-year CIN3+ risk for all HC2-positive women with ASC-US was 5.2%; this establishes the "benchmark" risk for colposcopic referral. Hierarchically, 3-year cumulative risks for each typing channel were 16.0% for HPV16, 7.4% for HPV18, 7.0% for HPV31, 7.1% for grouped HPV33/58, 4.3% for HPV52, 3.9% for HPV45, 2.7% for HPV51, 1.6% for HPV39/68/35, and 1.3% for HPV59/56/66.ASC-US linked to HPV16, HPV18, HPV31, or HPV33/58 warrants immediate colposcopy. Optimal management of women with HPV52 or HPV45 is uncertain. Risk of women with only HPV51, HPV39/68/35, or HPV59/56/66 might be low enough to recommend 1-year retesting permitting viral clearance. This strategy would defer colposcopy for 40% of women with HPV-positive ASC-US, half of whom would be cotest-negative at 1-year return. Approximately 10% of those with CIN3 diagnosable at enrollment would be delayed 1year instead. Cost-effectiveness analyses are needed.
- Published
- 2015
30. A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: Evidence against retesting
- Author
-
Philip E. Castle, Brandon LaMere, Mark Stanley, Nancy Poitras, Walter Kinney, Barbara Fetterman, Mark Schiffman, Jen Shieh, and Thomas Lorey
- Subjects
medicine.medical_specialty ,Uterine Cervical Neoplasms ,Lower risk ,California ,Article ,Virology ,Cytology ,Humans ,Mass Screening ,Medicine ,Early Detection of Cancer ,Mass screening ,Gynecology ,Colposcopy ,Cervical cancer ,Insurance, Health ,Cervical screening ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Health Maintenance Organizations ,medicine.disease ,Triage ,United States ,Test (assessment) ,Female ,business - Abstract
Infection with one or more high-risk HPV (hr-HPV) types is a necessary step in the development of cervical cancer, making its detection a useful tool for cervical cancer screening and prevention (Bosch et al., 2002). Hybrid Capture 2 (HC2, Qiagen, Gaithersburg, MD) was the first FDA-approved and is still the most widely used laboratory test for the presence of high-risk HPV DNA as a predictor of who is or is not at risk for cervical cancer and pre-cancer (defined here as cervical intraepithelial neoplasia grade 2 or worse). While HC2 has remarkable sensitivity for cervical intraepithelial neoplasia grade 2 or worse, the transient nature of most hr-HPV infections reduces its specificity as most infections are benign and will resolve without progressing to cervical intraepithelial neoplasia grade 2 or worse. This can be problematic for cervical cancer screening algorithms in which HPV positivity triggers more intensive follow-up; in such algorithms, good specificity is important for reducing the number of costly colposcopic follow-up visits (Cuzick et al., 2008). Although manufacturer specifications indicate a relative light unit (RLU) ratio compared with positive control of 1.0 as the threshold for determining positivity, reclassifying HC2 specimens that are equivocal and fall just above the positive cut-off is one potential way to improve the assay’s specificity (Rijkaart et al., 2010; Rebolj et al., 2011; Sasieni and Castanon, 2011). Some researchers have looked at increasing the RLU cut-off point because HC2 results at this level predict lower risk than higher values (Lorincz et al., 2002). However, equivocal results are not that common and raising the cut-point to 2.0 or 3.0 may only yield a modest improvement in specificity at some cost to sensitivity; i.e., misclassification of women with cervical intraepithelial neoplasia grade 2 or worse lesions whose RLU ratios are equivocal (Rijkaart et al., 2010). Rather than raising the cut-point, a more conservative approach is to repeat the HC2 test on specimens with equivocal results and determine the final test result based on a collective assessment of the test results (Knoepp et al., 2007), however this method requires additional laboratory time and cost to implement, weighing against any savings it yields from reducing the number of colposcopic examinations. In 2001 Kaiser Permanente Northern California added the HC2 assay to its cervical cancer screening program as a triage test for women with a cytologic diagnosis of atypical squamous cells of undetermined significance and, in 2003, as a concurrent test (“cotest”) with cytology for women 30 and older. In the cotesting scheme, women have been managed as follows: 1) women who are HPV-positive with a cytologic diagnosis of atypical squamous cells of undetermined significance, or have more severe (regardless of the HPV test results) are referred for immediate colposcopy; 2) women who test HPV-negative and have cytology of atypical squamous cells of undetermined significance, or who test HPV-positive with negative cytology are rescreened in one year; and 3) if both tests are negative, women are rescreened in three years. For cotests with borderline positive hr-HPV results, interpretation of the repeat test results is used to determine the final hr-HPV test result and hence the need for rescreening visits versus colposcopy. At the time that HC2 was introduced into the Kaiser Permanente Northern California cervical cancer screening algorithm, based on concern over the meaning of borderline-positive HC2-positive results, it was decided that any specimens with borderline or “equivocal” HC2 results, defined as a RLU ratio greater than or equal to 1.0 but less than 3.0, would be re-tested two additional times. The final hr-HPV result was determined by the majority results of the three tests i.e., only one of the two repeats needed to be positive to have the final positive hr-HPV result. To assess the utility of Kaiser Permanente Northern California’s re-testing scheme for equivocal HC2 specimens, HC2 data, cytology results, and histological outcomes (less than cervical intraepithelial neoplasia grade 2, cervical intraepithelial neoplasia grade 2 or worse) were compiled for patients undergoing routine cervical cancer screening at Kaiser Permanente Northern California.
- Published
- 2013
31. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women
- Author
-
Thomas Lorey, Walter Kinney, Clara Bodelon, Diane Tokugawa, Philip E. Castle, Nancy Poitras, Barbara Fetterman, Mark Schiffman, Shannon N. Wood, Eric Stiemerling, and Nicolas Wentzensen
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Cervix Uteri ,Stain ,Risk Assessment ,Sensitivity and Specificity ,Article ,Predictive Value of Tests ,Risk Factors ,Cytology ,Biomarkers, Tumor ,Medicine ,Humans ,Mass Screening ,Clinical significance ,Prospective Studies ,Papillomaviridae ,Prospective cohort study ,Referral and Consultation ,Mass screening ,Cyclin-Dependent Kinase Inhibitor p16 ,Early Detection of Cancer ,Gynecology ,Colposcopy ,biology ,medicine.diagnostic_test ,business.industry ,Papillomavirus Infections ,Middle Aged ,biology.organism_classification ,Neoplasm Proteins ,Ki-67 Antigen ,Oncology ,Predictive value of tests ,Female ,business ,Precancerous Conditions - Abstract
BACKGROUND Human papillomavirus (HPV)-based cervical cancer screening requires triage markers to decide who should be referred to colposcopy. p16/Ki-67 dual stain cytology has been proposed as a biomarker for cervical precancers. We evaluated the dual stain in a large population of HPV-positive women. METHODS One thousand five hundred and nine HPV-positive women screened with HPV/cytology cotesting at Kaiser Permanente California were enrolled into a prospective observational study in 2012. Dual stain cytology was performed on residual Surepath material, and slides were evaluated for dual stain-positive cells. Disease endpoints were ascertained from the clinical database at KPNC. We evaluated the clinical performance of the assay among all HPV-positive women and among HPV-positive, cytology-negative women. We used internal benchmarks for clinical management to evaluate the clinical relevance of the dual stain assay. We evaluated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the dual stain compared with Pap cytology. All statistical tests were two-sided. RESULTS The dual stain had lower positivity (45.9%) compared with cytology at an ASC-US threshold (53.4%). For detection of CIN2+, the dual stain had similar sensitivity (83.4% vs 76.6%, P = .1), and statistically higher specificity (58.9% vs 49.6%, P < .001), PPV (21.0% vs 16.6%, P < .001), and NPV (96.4% vs 94.2%, P = .01) compared with cytology. Similar patterns were observed for CIN3+. Women with a positive test had high enough risk for referral to colposcopy, while the risk for women with negative tests was below a one-year return threshold based on current US management guidelines. CONCLUSION Dual stain cytology showed good risk stratification for all HPV-positive women and for HPV-positive women with normal cytology. Additional follow-up is needed to determine how long dual stain negative women remain at low risk of precancer.
- Published
- 2014
32. Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men
- Author
-
Julia C. Gage, Jie Chen, Barbara Fetterman, Thomas Lorey, Mark Sadorra, Vikrant V. Sahasrabuddhe, Sylvia Borgonovo, Philip E. Castle, Teresa M. Darragh, Diane Tokugawa, Sean Boyle, Scott Dahai Tang, Stephen Follansbee, Nicolas Wentzensen, and Munson, E
- Subjects
Male ,Genotyping Techniques ,Medical and Health Sciences ,Men who have sex with men ,Cytology ,Papillomaviridae ,Cancer ,education.field_of_study ,biology ,Incidence (epidemiology) ,virus diseases ,Homosexuality ,Middle Aged ,Biological Sciences ,female genital diseases and pregnancy complications ,Hpv testing ,Infectious Diseases ,HIV/AIDS ,Infection ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,Cytological Techniques ,Sexual and Gender Minorities (SGM/LGBT*) ,Sensitivity and Specificity ,Microbiology ,Young Adult ,Clinical Research ,Virology ,medicine ,Anal cancer ,Humans ,Homosexuality, Male ,education ,Gynecology ,Anus Diseases ,Agricultural and Veterinary Sciences ,business.industry ,Prevention ,Papillomavirus Infections ,biology.organism_classification ,medicine.disease ,Sexually Transmitted Infections ,business ,Digestive Diseases - Abstract
Anal human papillomavirus (HPV) infections are common, and the incidence of anal cancer is high in HIV-infected men who have sex with men (MSM). To evaluate the performance of HPV assays in anal samples, we compared the cobas HPV test (cobas) to the Roche Linear Array HPV genotyping assay (LA) and cytology in HIV-infected MSM. Cytology and cobas and LA HPV testing were conducted for 342 subjects. We calculated agreement between the HPV assays and the clinical performance of HPV testing and HPV genotyping alone and in combination with anal cytology. We observed high agreement between cobas and LA, with cobas more likely than LA to show positive results for HPV16, HPV18, and other carcinogenic types. Specimens testing positive in cobas but not in LA were more likely to be positive for other markers of HPV-related disease compared to those testing negative in both assays, suggesting that at least some of these were true positives for HPV. cobas and LA showed high sensitivities but low specificities for the detection of anal intraepithelial neoplasia grade 2/3 (AIN2/3) in this population (100% sensitivity and 26% specificity for cobas versus 98.4% sensitivity and 28.9% specificity for LA). A combination of anal cytology and HPV genotyping provided the highest accuracy for detecting anal precancer. A higher HPV load was associated with a higher risk of AIN2/3 with HPV16 ( P trend < 0.001), HPV18 ( P trend = 0.07), and other carcinogenic types ( P trend < 0.001). We demonstrate that cobas can be used for HPV detection in anal cytology specimens. Additional tests are necessary to identify men at the highest risk of anal cancer among those infected with high-risk HPV.
- Published
- 2014
33. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening
- Author
-
Nicolas, Wentzensen, Barbara, Fetterman, Diane, Tokugawa, Mark, Schiffman, Philip E, Castle, Shannon N, Wood, Eric, Stiemerling, Nancy, Poitras, Thomas, Lorey, and Walter, Kinney
- Subjects
Adult ,Observer Variation ,Vaginal Smears ,Staining and Labeling ,Cytodiagnosis ,Papillomavirus Infections ,Reproducibility of Results ,Uterine Cervical Neoplasms ,Reference Standards ,Prognosis ,Uterine Cervical Dysplasia ,Sensitivity and Specificity ,Neoplasm Proteins ,Ki-67 Antigen ,Colposcopy ,Biomarkers, Tumor ,Carcinoma, Squamous Cell ,Humans ,Female ,Neoplasm Grading ,Papillomaviridae ,Cyclin-Dependent Kinase Inhibitor p16 ,Early Detection of Cancer ,Follow-Up Studies - Abstract
Dual-stain cytology for p16 and Ki-67 has been proposed as a biomarker in cervical cancer screening. The authors evaluated the reproducibility and accuracy of dual-stain cytology among 10 newly trained evaluators.In total, 480 p16/Ki-67-stained slides from human papillomavirus-positive women were evaluated in masked fashion by 10 evaluators. None of the evaluators had previous experience with p16 or p16/Ki-67 cytology. All participants underwent p16/Ki-67 training and subsequent proficiency testing. Reproducibility of dual-stain cytology was measured using the percentage agreement, individual and aggregate κ values, as well as McNemar statistics. Clinical performance for the detection of cervical intraepithelial neoplasia grade 2 or greater (CIN2+) was evaluated for each individual evaluator and for all evaluators combined compared with the reference evaluation by a cytotechnologist who had extensive experience with dual-stain cytology.The percentage agreement of individual evaluators with the reference evaluation ranged from 83% to 91%, and the κ values ranged from 0.65 to 0.81. The combined κ value was 0.71 for all evaluators and 0.73 for cytotechnologists. The average sensitivity and specificity for the detection of CIN2+ among novice evaluators was 82% and 64%, respectively; whereas the reference evaluation had 84% sensitivity and 63% specificity, respectively. Agreement on dual-stain positivity increased with greater numbers of p16/Ki-67-positive cells on the slides.Good to excellent reproducibility of p16/Ki-67 dual-stain cytology was observed with almost identical clinical performance of novice evaluators compared with reference evaluations. The current findings suggest that p16/Ki-67 dual-stain evaluation can be implemented in routine cytology practice with limited training.
- Published
- 2014
34. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management
- Author
-
Julia C, Gage, Hormuzd A, Katki, Mark, Schiffman, Philip E, Castle, Barbara, Fetterman, Nancy E, Poitras, Thomas, Lorey, Li C, Cheung, Catherine, Behrens, Abha, Sharma, Fang-Hui, Zhao, Jack, Cuzick, Zi Hua, Yang, and Walter K, Kinney
- Subjects
Adult ,Vaginal Smears ,Time Factors ,Uterine Cervical Neoplasms ,Middle Aged ,Uterine Cervical Dysplasia ,Risk Assessment ,United States ,Risk Factors ,Practice Guidelines as Topic ,Atypical Squamous Cells of the Cervix ,Humans ,Mass Screening ,Female ,Precancerous Conditions ,Early Detection of Cancer ,Papanicolaou Test - Abstract
Different US practice guidelines have conflicting recommendations for when women should return after a screening result of human papillomavirus (HPV)-negative with an equivocal Papanicolaou (Pap) result of atypical squamous cells of undetermined significance (ASC-US) (ie, return in either 3 or 5 years). One way to determine management is to compare the risk of precancer/cancer after an HPV-negative/ASC-US result with the risks after other negative screening results. For example, if the risk after an HPV-negative/ASC-US result was similar to the risk after a negative Pap test, a 3-year return would be preferred because guidelines agree that women with negative Pap test results should return in 3 years. Alternatively, if the risk after an HPV-negative/ASC-US result is similar to that after a cotest-negative result (HPV negative/Pap test negative), a 5-year return would be preferred because guidelines agree that women testing cotest negative should return in 5 years.The authors compared risks of cervical intraepithelial neoplasia of grade 3 or higher (CIN3+) and cervical cancer among women aged 30 years to 64 years at Kaiser Permanente Northern California with the following test results from 2003 through 2012: 17,191 women testing HPV negative/ASC-US; 980,268 women testing Pap test negative (regardless of HPV result); and 892,882 women testing cotest negative.The 5-year CIN3+ and cancer risks after an HPV-negative/ASC-US result were closer to the risks after a negative Pap test result (CIN3+: 0.48% vs 0.31% [P =.0019]; and cancer: 0.043% vs 0.031% [P =.4]) than after a negative cotest (CIN3+: 0.48% vs 0.11% [P.0001]; and cancer: 0.043% vs 0.014% [P =.016]).Women testing HPV negative/ASC-US were found to have precancer/cancer risks that were more closely aligned with women with negative Pap test results, suggesting that women testing HPV negative/ASC-US should be managed similarly to women testing negative on Pap tests with a 3-year return for screening.
- Published
- 2014
35. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection
- Author
-
Julia C, Gage, Hormuzd A, Katki, Mark, Schiffman, Barbara, Fetterman, Nancy E, Poitras, Thomas, Lorey, Li C, Cheung, Philip E, Castle, and Walter K, Kinney
- Subjects
Adult ,Risk ,Vaginal Smears ,Papillomavirus Infections ,Age Factors ,Uterine Cervical Neoplasms ,Alphapapillomavirus ,Middle Aged ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Article ,Cohort Studies ,Humans ,Mass Screening ,Female ,Neoplasm Grading ,Precancerous Conditions ,Early Detection of Cancer ,Papanicolaou Test - Abstract
It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with "newly detected" HPV infections at their second screening visit. Women (57,899, 6.0%) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3%) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p 0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5% versus 3.9%, (p 0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4% versus 7.4% (p = 0.017) for enrollment HPV and 5.1% versus 3.5% (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.
- Published
- 2014
36. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men
- Author
-
Diane Tokugawa, Nicolas Wentzensen, Lauren Schwartz, Thomas Lorey, Philip E. Castle, Julia C. Gage, Patricia Luhn, Stephen Follansbee, Sylvia Borgonovo, Teresa M. Darragh, Vikrant V. Sahasrabuddhe, and Barbara Fetterman
- Subjects
Oncology ,Male ,viruses ,Anal Canal ,men who have sex with men ,HIV Infections ,Medical and Health Sciences ,California ,Men who have sex with men ,Risk Factors ,HIV Seropositivity ,Immunology and Allergy ,2.2 Factors relating to the physical environment ,Stage (cooking) ,Aetiology ,human papillomavirus ,Papillomaviridae ,Cancer ,Cervical cancer ,human immunodeficiency virus ,Incidence (epidemiology) ,Smoking ,HPV infection ,virus diseases ,Homosexuality ,Middle Aged ,Biological Sciences ,Anus Neoplasms ,female genital diseases and pregnancy complications ,Natural history ,medicine.anatomical_structure ,Infectious Diseases ,HIV/AIDS ,Infection ,Adult ,medicine.medical_specialty ,Adolescent ,anal cancer ,Sexual Behavior ,Sexual and Gender Minorities (SGM/LGBT*) ,Microbiology ,Major Articles and Brief Reports ,Young Adult ,anal intraepithelial neoplasia ,Clinical Research ,Internal medicine ,medicine ,Confidence Intervals ,Anal cancer ,Humans ,Homosexuality, Male ,Demography ,Gynecology ,business.industry ,Prevention ,Papillomavirus Infections ,Chlamydia Infections ,medicine.disease ,Anus ,CD4 Lymphocyte Count ,Good Health and Well Being ,Logistic Models ,Sexually Transmitted Infections ,business ,Digestive Diseases ,Precancerous Conditions - Abstract
Anal cancer is relatively uncommon in the United States, with an expected 6000 new cases in 2012 and an overall annual incidence rate of 2/100 000 [1, 2]. Most anal cancers are caused by human papillomavirus (HPV) infection [3]. Certain populations, such as human immunodeficiency virus (HIV)–infected and other immunosuppressed individuals, appear to have an increased risk of both HPV infection and anal cancer. A recent worldwide metaanalysis showed that HIV-infected men who have sex with men (MSM) have an estimated 46/100 000 incident anal cancer cases per year compared with HIV-negative MSM who have 5/100 000 incident cases per year [4]. Since the advent of highly active antiretroviral therapy (HAART), the life expectancy for HIV-infected individuals has significantly increased. This may have allowed time for progression of carcinogenic HPV infections to anal cancer and possibly explains an increase in anal cancer incidence in the United States [5–8]. Anal cancer natural history presumably follows the same steps as cervical cancer natural history: HPV acquisition, HPV persistence, progression of persistent HPV infections to high-grade anal intraepithelial neoplasia (AIN), and invasion to anal cancer [5]. Studies have identified risk factors for each stage in the progression from cervical HPV infection to cervical cancer [9–11], and we are beginning to find similar risk factors in anal cancer natural history. Risk factors for anal HPV infection are related to sexual behavior, such as lifetime number of sexual partners, as well as low CD4 count in HIV-infected populations [12–15]. Smoking history has been shown to be associated with anal HPV persistence [16, 17] and anal cancer [18, 19], but it is unclear at what stage smoking influences the natural history. To add to our understanding of risk factors that influence the natural history of HPV and anal cancer, we conducted a study of lifestyle characteristics and clinical parameters for HIV-infected MSM undergoing routine anal cancer screening at Kaiser Permanente Northern California (KPNC) Health Maintenance Organization.
- Published
- 2013
37. Determining the Utility and Effectiveness of the NeoPath AutoPap 300 QC System Used Routinely
- Author
-
Gene Pawlick, James S. Hartinger, Carol Gilbert, Barbara Fetterman, Sheryl Connell, and Howard Koo
- Subjects
Quality Control ,medicine.medical_specialty ,Histology ,Biopsy ,Uterine Cervical Neoplasms ,Atypical Squamous Cells ,Pathology and Forensic Medicine ,Cytology ,Image Processing, Computer-Assisted ,medicine ,Humans ,False Negative Reactions ,Vaginal Smears ,Baseline values ,Gynecology ,Pathology, Clinical ,medicine.diagnostic_test ,business.industry ,General Medicine ,Laboratories, Hospital ,Diagnostic quality ,Current practice ,Female ,business ,Nuclear medicine ,Ascus - Abstract
Objective To evaluate routine use of the NeoPath AutoPap 300 QC System (AP 300) as it influences diagnostic quality and operations in a large cytology laboratory. Study design During a three-month period, 35,143 conventionally prepared consecutive cervical cytologic smears taken from non-high-risk women and evaluated as negative by our staff of 25 cytotechnologists were selected for processing by four AP 300 instruments. Slides flagged for review by the AP 300 were reevaluated by our five quality control (QC) cytotechnologists. False negative (FN) results were compared with results of our current practice (CP), random-selection QC method, used during the preceding six months. Results A 240% increase was seen in the FN detection rate for atypical squamous cells of undetermined significance (ASCUS) and squamous intraepithelial lesions (SIL) (n AP = 65 FN in 5,034 QC, n CP = 77 FN in 22,052 QC) and a 744% increase in the FN detection rate for low and high grade SIL (n AP = 24 FN/5,034 QC, n CP = 12 FN/22,052 QC). The rate of overcall by cytotechnologists did not increase. The QC ASCUS/SIL ratio improved. FN biopsy correlation increased from 45% to 85% (n CP = 17/38 agreement, n AP = 23/27 agreement). Turnaround time increased by one or more days for negative and 1.5 days for QC result reporting. Sensitivity varied among instruments. Conclusion More FN results and greater specificity were seen using the AP 300 than using CP. As with other instrumentation, each laboratory should establish acceptable ranges of performance and baseline values for sensitivity and specificity.
- Published
- 1999
38. Risk of cervical precancer and cancer in women with cervical intraepithelial neoplasia grade 1 on endocervical curettage
- Author
-
Emily Y. Fukuchi, Thomas Lorey, Barbara Fetterman, Ramey D. Littell, Walter Kinney, and Nancy Poitras
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Uterine Cervical Neoplasms ,Endocervical curettage ,Adenocarcinoma ,urologic and male genital diseases ,Cervical intraepithelial neoplasia ,Ectocervical Biopsy ,Risk Assessment ,California ,Curettage ,Medicine ,Humans ,Cumulative incidence ,neoplasms ,Gynecology ,Cervical screening ,business.industry ,virus diseases ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,stomatognathic diseases ,Squamous intraepithelial lesion ,Cohort ,Female ,business - Abstract
Objective This study aimed to characterize the 24-month risk of cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) and grade 3 or worse (CIN 3+) in women with low-risk cytological finding and CIN 1 on endocervical curettage (ECC). Materials and methods Cervical screening tests and cervical biopsy results from Kaiser Permanente Northern California were reviewed for years 2004 to 2008. Women with index cytological result of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion who underwent excisional procedure within 24 months of CIN 1 diagnosis were grouped by ECC status. A third cohort comprised women with ECC-CIN 1 followed up without excisional procedure. The 24-month cumulative incidence of CIN 2+ and CIN 3+ was calculated for each cohort. Results Excisional procedures were performed in 224 women; 54 had ECC-CIN 1 with ectocervical biopsy CIN 1 or less, and 170 had ectocervical CIN 1 with negative ECC finding. The 24-month risk of CIN 2+ was lower in the ECC-CIN 1 cohort compared with the ECC-negative (ectocervical CIN 1) cohort (24.1 vs 44.7%, p = .018) and nonsignificantly lower for CIN 3+ (7.4% vs 14.1%, p = .23). Among 203 women with ECC-CIN 1 followed up without excisional procedure but with follow-up ECC at a median of 21.7 months from index ECC, CIN 2 was found in 21 (10.3%, 95% CI = 6.7%-15.6%), and CIN 3 was found in 3 (1.5%, 95% CI = 0.4%-4.6%). Conclusions A diagnosis of CIN 1 on ECC preceded by atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion does not increase the risk of CIN 2+ compared with women with ectocervical CIN 1 and negative ECC. The risk of CIN 2+ in women followed up without excisional procedure is sufficiently low that it is reasonable to offer conservative management similar to that for ectocervical CIN 1.
- Published
- 2013
39. Follow-up testing post-colposcopy: Five-year risk of CIN2+ after a colposcopic diagnosis of CIN1 or less
- Author
-
Hormuzd A. Katki, Tina Raine-Bennett, Philip E. Castle, Walter Kinney, Mark Schiffman, Barbara Fetterman, Li C. Cheung, Nancy Poitras, Julia C. Gage, and Thomas Lorey
- Subjects
Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Pancreatitis-Associated Proteins ,Atypical Squamous Cells ,Lower risk ,Negative Test Result ,Risk Assessment ,Article ,California ,Cohort Studies ,Virology ,medicine ,Humans ,Mass Screening ,Gynecology ,Colposcopy ,Vaginal Smears ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Squamous intraepithelial lesion ,Female ,Risk assessment ,business ,Ascus ,Cohort study - Abstract
Most women referred for colposcopy are not diagnosed with cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) but, nonetheless, are typically asked to return much sooner than their next routine screening interval in 3 to 5 years. An important question is how many subsequent negative Pap results, or negative Pap and human papillomavirus (HPV) cotest results, are needed before returning to an extended retesting interval.We estimated 5-year risks of CIN 2+ for 3 follow-up management strategies after colposcopy (Pap-alone, HPV-alone, and cotesting) for 20,319 women aged 25 years and older screened from 2003 to 2010 at Kaiser Permanente Northern California who were referred for colposcopy but for whom CIN 2+ was not initially diagnosed (i.e., "women with CIN 1/negative colposcopy").Screening results immediately antecedent to CIN 1/negative colposcopy influenced subsequent 5-year CIN 2+ risk: women with an antecedent HPV-positive/atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) Pap had a lower risk (10%) than those with antecedent atypical squamous cells cannot rule out HSIL (ASC-H; 16%, p.0001) or high-grade squamous intraepithelial lesion or worse (HSIL+; 24%, p.0001). For women with an antecedent HPV-positive/ASC-US or LSIL, a single negative cotest approximately 1 year after colposcopy predicted lower subsequent 5-year risk of CIN 2+ (1.1%) than 2 sequential negative HPV tests (1.8%, p = .3) or 2 sequential negative Pap results (4.0%, p.0001). For those with an antecedent ASC-H or HSIL+ Pap, 1 negative cotest 1 year after colposcopy predicted lower subsequent 5-year risk of CIN 2+ (2.2%) than 1 negative HPV test (4.4%, p = .4) or 1 negative Pap (7.0%, p = .06); insufficient data existed to calculate the risk after sequential negative cotests for women with high-grade antecedent cytology.Women with a CIN 1/negative colposcopy followed by negative postcolposcopy tests did not achieve sufficiently low CIN 2+ risk to return to 5-year routine screening. For women with antecedent HPV-positive/ASC-US or LSIL, a single negative postcolposcopy cotest reduced their risk to a level consistent with a 3-year return. For women with antecedent ASC-H or HSIL+, no single negative test result sufficed to reduce their risk to a level consistent with a 3-year return.
- Published
- 2013
40. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines
- Author
-
Mark Schiffman, Thomas Lorey, Walter Kinney, Barbara Fetterman, Julia C. Gage, Philip E. Castle, Nancy Poitras, Tina Raine-Bennett, Li C. Cheung, and Hormuzd A. Katki
- Subjects
Adult ,medicine.medical_specialty ,MEDLINE ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Article ,Virology ,medicine ,Humans ,Mass Screening ,Mass screening ,Gynecology ,Vaginal Smears ,Cancer prevention ,Cervical screening ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,Cancer ,General Medicine ,Benchmarking ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Hpv testing ,Family medicine ,Female ,business - Abstract
In 2012, the US Preventive Services Task Force (USPSTF) and a consensus of 25 organizations endorsed concurrent cytology and human papillomavirus (HPV) testing ("cotesting") for cervical cancer screening. Past screening and management guidelines were implicitly based on risks defined by Pap-alone, without consideration of HPV test results. To promote management that is consistent with accepted practice, new guidelines incorporating cotesting should aim to achieve equal management of women at equal risk of cervical intraepithelial neoplasia grade 3 and cancer (CIN 3+).We estimated cumulative 5-year risks of CIN 3+ for 965,360 women aged 30 to 64 years undergoing cotesting at Kaiser Permanente Northern California over 2003 to 2010. We calculated the implicit risk thresholds for Pap-alone and applied them for new management guidance on HPV and Pap cotesting, citing 2 examples: HPV-positive/atypical squamous cells of undetermined significance (ASC-US) and HPV-negative/Pap-negative. We call this guidance process "benchmarking."A low-grade squamous intraepithelial lesion result, for which immediate colposcopy is prescribed, carries a 5-year CIN 3+ risk of 5.2%, suggesting that test results with similar risks should be managed with colposcopy. Similarly, ASC-US (2.6% risk) is managed with a 6- to 12-month follow-up visit and Pap-negative (0.26% risk) is managed with a 3-year follow-up visit. The 5-year CIN 3+ risk for women with HPV-positive/ASC-US was 6.8% (95% confidence interval = 6.2%-7.6%). This is greater than the 5.2% risk implicitly leading to referral to colposcopy, consistent with current management recommendations that HPV-positive/ASC-US should be referred for immediate colposcopy. The 5-year CIN 3+ risk for women with HPV-negative/Pap-negative was 0.08% (95% confidence interval = 0.07%-0.09%), far below the 0.26% implicitly required for a 3-year return and justifying a longer (e.g., 5-year) return.Using the principle of "equal management of equal risks," benchmarking to implicit risk thresholds based on Pap-alone can be used to achieve safe and consistent incorporation of cotesting.
- Published
- 2013
41. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results
- Author
-
Li C. Cheung, Hormuzd A. Katki, Mark Schiffman, Barbara Fetterman, Julia C. Gage, Nancy Poitras, Tina Raine-Bennett, Thomas Lorey, Philip E. Castle, and Walter Kinney
- Subjects
Adult ,medicine.medical_specialty ,Referral ,Uterine Cervical Neoplasms ,Context (language use) ,Cervical intraepithelial neoplasia ,Risk Assessment ,California ,Article ,Cohort Studies ,Virology ,medicine ,Humans ,Mass Screening ,Mass screening ,Gynecology ,Colposcopy ,Cervical cancer ,Vaginal Smears ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Papillomavirus Infections ,Obstetrics and Gynecology ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Female ,Risk assessment ,business - Abstract
High-grade Pap results (e.g., atypical glandular cells [AGC], atypical squamous cells cannot rule out HSIL [ASC-H], and high-grade squamous intraepithelial lesion [HSIL]) predict high cancer risks, resulting in referral for colposcopy without HPV triage. However, new guidelines recommending cotesting for women 30 years and older imply that clinicians will often receive the HPV test result concurrently for high-grade Pap results. We examined whether HPV testing provides useful risk stratification in this context.From a cohort of 965,360 women aged 30 to 64 years undergoing cotesting at Kaiser Permanente Northern California, we estimated 5-year risks for cervical cancer and CIN 3+ after AGC (2,074 women), ASC-H (1,647 women), and HSIL (2,019 women) according to HPV test results.HPV positivity of AGC Pap results was 25% and decreased with age (30 to 34 vs 60 to 64 years, 44% vs 17%, p.0001), whereas HPV positivity of ASC-H and HSIL was much higher (71% and 94%) and decreased less with age. Even for these high-grade Pap results, 5-year CIN 3+ risks differed substantially between HPV-positive and HPV-negative women (AGC, 33% vs 0.93%, p.0001; ASC-H, 25% vs 3.5%, p.0001; HSIL, 49% vs 30%, p = .006). However, except for AGC, cervical cancer risks differed less between HPV-positive and HPV-negative women (AGC, 9.0% vs 0.37%, p.0001; ASC-H, 2.5% vs 2.1%, p = .8; HSIL, 6.6% vs 6.8%, p = .7).The risks of CIN 3+ among women with HPV-negative high-grade Pap results were lower than those among women with HPV-positive high-grade Pap results, especially after AGC. However, by the principle of "equal management of equal risks," all HPV-negative high-grade Pap results had cancer risks high enough to warrant colposcopy, confirming that there is no current role for HPV triage of high-grade Pap results.
- Published
- 2013
42. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management
- Author
-
Julia C. Gage, Philip E. Castle, Mark Schiffman, Barbara Fetterman, Hormuzd A. Katki, Nancy Poitras, Walter Kinney, Li C. Cheung, Tina Raine-Bennett, and Thomas Lorey
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Adenocarcinoma ,Cervical intraepithelial neoplasia ,Risk Assessment ,California ,Article ,Cohort Studies ,Cervical intraepithelial neoplasia grade 2 ,Recurrence ,Internal medicine ,Virology ,medicine ,Humans ,Mass Screening ,Mass screening ,Aged ,Gynecology ,Aged, 80 and over ,Vaginal Smears ,Cancer prevention ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Female ,Risk assessment ,business ,After treatment ,Cohort study - Abstract
After excisional treatment, cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) can recur. It is not clear how many negative posttreatment Pap or cotest results are needed to ensure adequate safety against CIN 2+ before returning to extended retesting intervals.We observed 5-year risks of CIN 2+ for 3 follow-up management strategies after treatment (Pap-alone, human papillomavirus [HPV]-alone, and HPV/Pap cotesting) for 3,273 women aged 25 years and older who were treated for CIN 2, CIN 3, or adenocarcinoma in situ (AIS) between 2003 and 2010 at Kaiser Permanente Northern California.Five-year risks of recurrent CIN 2+ after treatment varied both by antecedent screening test result and the histology of the treated lesion. The risk ranged from 5% for CIN 2 preceded by HPV-positive/atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion to 16% for CIN 3/AIS preceded by atypical glandular cells (AGC)/atypical squamous cells cannot rule out high-grade squamous intraepithelial lesion (ASC-H)/high-grade squamous intraepithelial lesion or worse (HSIL+) (p.0001). However, after posttreatment negative tests, risks were lowered and similar regardless of antecedent screening test and histology of treated disease. The 5-year recurrent CIN 2+ risk after a negative posttreatment cotest (2.4%) was lower than that following a negative HPV test (3.7%, p = .3) or negative Pap result (4.2%, p = .1). Two negative posttreatment tests of each kind conferred slightly lower 5-year CIN 2+ risk than one (2 negative Pap tests vs. 1, 2.7% vs 4.2%, p = .2; 2 negative HPV tests vs. 1, 2.7% vs 3.7%, p = .7; 2 negative cotests vs. 1, 1.5% vs 2.4%, p = .8). The 5-year CIN 2+ risk after 2 negative cotests of 1.5% (95% confidence interval = 0.3%-7.2%) approached the 0.68% risk after a negative Pap test during routine screening.Women with antecedent AGC/ASC-H/HSIL+ Pap results or those treated for CIN 3/AIS had a substantial risk of developing CIN 2+ posttreatment. On the basis of the principle of "equal management of equal risks," after negative test results posttreatment, no subgroup of women achieved risk sufficiently low to return to 5-year routine screening. However, negative cotests after treatment provided more reassurance against recurrent CIN 2+ than either negative Pap tests or HPV tests alone.
- Published
- 2013
43. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men
- Author
-
Mark Sadorra, Thomas Lorey, Barbara Fetterman, Brandon LaMere, Lauren Schwartz, Scott Dahai Tang, Philip E. Castle, Diane Tokugawa, Sean Boyle, Sylvia Borgonovo, Teresa M. Darragh, Julia C. Gage, Stephen Follansbee, Vikrant V. Sahasrabuddhe, and Nicolas Wentzensen
- Subjects
Male ,Prevalence ,men who have sex with men ,HIV Infections ,Medical and Health Sciences ,Men who have sex with men ,Immunology and Allergy ,Papillomaviridae ,human papillomavirus ,Cancer ,education.field_of_study ,biology ,human immunodeficiency virus ,Coinfection ,virus diseases ,Middle Aged ,attribution ,Biological Sciences ,Anus Neoplasms ,female genital diseases and pregnancy complications ,Infectious Diseases ,HIV/AIDS ,Infection ,Carcinoma in Situ ,Adult ,medicine.medical_specialty ,Genotype ,Sexual Behavior ,Population ,HPV vaccines ,Microbiology ,Vaccine Related ,Papillomavirus Vaccines ,Major Articles and Brief Reports ,anal intraepithelial neoplasia ,genotypes ,Internal medicine ,medicine ,Anal cancer ,Humans ,education ,Aged ,business.industry ,Prevention ,Papillomavirus Infections ,medicine.disease ,biology.organism_classification ,Good Health and Well Being ,Cross-Sectional Studies ,Immunology ,Sexually Transmitted Infections ,Immunization ,Neoplasm Grading ,business ,Digestive Diseases - Abstract
Background. The prevention of human papillomavirus (HPV)–induced anal cancer in high-risk populations such as human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) remains an urgent priority, given rising incidence rates despite widespread antiretroviral therapy use. Methods. HPV genotypes and anal disease prevalence, by cytology and histopathologic findings, were evaluated among 363 HIV-infected MSM. We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to individual carcinogenic HPV genotypes and estimated the range of the proportion of HGAIN cases potentially preventable by prophylactic HPV vaccines. Results. HPV16 was the most common genotype overall (26.4% of cases) and among HGAIN cases (55%). Prevalence of multiple (≥2) carcinogenic HPV genotypes increased from 30.9% in cases of AIN grade
- Published
- 2013
44. A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men
- Author
-
Brandon LaMere, Sylvia Borgonovo, Teresa M. Darragh, Nicolas Wentzensen, Lauren Schwartz, Philip E. Castle, Julia C. Gage, Diane Tokugawa, Stephen Follansbee, Ana Cecilia Rodriguez, Barbara Fetterman, and Thomas Lorey
- Subjects
Male ,Epidemiology ,Messenger ,HIV Infections ,Cervical Cancer ,Medical and Health Sciences ,Men who have sex with men ,chemistry.chemical_compound ,Genotype ,Prevalence ,Viral ,Cancer ,Human papillomavirus 16 ,Tumor ,medicine.diagnostic_test ,virus diseases ,Homosexuality ,Middle Aged ,Anus Neoplasms ,Prognosis ,female genital diseases and pregnancy complications ,Infectious Diseases ,Oncology ,HIV/AIDS ,Infection ,Adult ,Sexual Behavior ,Biology ,Lower risk ,Risk Assessment ,Sensitivity and Specificity ,Article ,Age Distribution ,Clinical Research ,Genetics ,Biomarkers, Tumor ,medicine ,Humans ,RNA, Messenger ,Homosexuality, Male ,Messenger RNA ,Papillomavirus Infections ,RNA ,Anoscopy ,DNA ,medicine.disease ,Virology ,Good Health and Well Being ,Cross-Sectional Studies ,chemistry ,DNA, Viral ,Sexually Transmitted Infections ,Precancerous Conditions ,Biomarkers - Abstract
Background: Human papillomavirus (HPV) RNA detection is reportedly more specific for the detection of anogenital precancer than HPV DNA but it is unknown whether this is due to detection of RNA or due to HPV genotype restriction. Methods: A total of 363 human immunodeficiency virus (HIV)–positive men who have sex with men had two anal cytology samples taken and were evaluated using high-resolution anoscopy and biopsies of visible lesions. Anal specimens were tested for E6/E7 RNA for five carcinogenic HPV genotypes (HPV16, 18, 31, 33, and 45) and tested for the DNA of 13 carcinogenic HPV genotypes. Results: DNA testing was more likely to be positive than RNA testing (53% vs. 48%; P = 0.02) for the same five HPV genotypes in aggregate. When restricted to five HPV genotypes targeted by the RNA test, the sensitivity to detect anal precancer was the same for DNA and RNA (81%), whereas RNA was more specific than DNA (65% vs. 58%; P = 0.007). In comparison, DNA detection of all 13 carcinogenic HPV genotypes was more sensitive (96% vs. 81%; P = 0.001) but much less specific (65% vs. 33%; P < 0.001) as compared with RNA detection of the five HPV genotypes. Conclusion: After controlling for HPV genotypes, RNA was only slightly more specific than DNA detection for anal precancer. Impact: DNA or RNA testing for a subset of the most carcinogenic HPV genotypes may be useful for distinguishing between those HPV-positive men at higher and lower risk of anal precancer and cancer. Cancer Epidemiol Biomarkers Prev; 22(1); 42–9. ©2012 AACR.
- Published
- 2013
45. Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM
- Author
-
Thomas Lorey, Julia C. Gage, Stephen Follansbee, Nicolas Wentzensen, Vikrant V. Sahasrabuddhe, Diane Tokugawa, Lauren Schwartz, Philip E. Castle, Barbara Fetterman, Brandon LaMere, Sylvia Borgonovo, and Teresa M. Darragh
- Subjects
Oncology ,Male ,Messenger ,Anal Canal ,p16 ,Cervical Cancer ,Medical and Health Sciences ,California ,Cytology ,Immunology and Allergy ,Viral ,human papillomavirus ,Cancer ,education.field_of_study ,Human papillomavirus 16 ,medicine.diagnostic_test ,biology ,Human papillomavirus 18 ,Homosexuality ,Middle Aged ,Biological Sciences ,Anus Neoplasms ,Neoplasm Proteins ,Infectious Diseases ,Ki-67 ,RNA, Viral ,HIV/AIDS ,Adult ,medicine.medical_specialty ,Genotype ,Immunology ,Population ,Clinical Trials and Supportive Activities ,Sensitivity and Specificity ,Article ,Acquired immunodeficiency syndrome (AIDS) ,Clinical Research ,Predictive Value of Tests ,Internal medicine ,Virology ,Biopsy ,medicine ,Genetics ,Anal cancer ,Humans ,RNA, Messenger ,MSM ,Homosexuality, Male ,education ,Genotyping ,Cyclin-Dependent Kinase Inhibitor p16 ,Aged ,human papillomavirus mRNA ,Gynecology ,business.industry ,anal cancer screening ,Papillomavirus Infections ,Psychology and Cognitive Sciences ,Anoscopy ,Reproducibility of Results ,HIV ,medicine.disease ,Good Health and Well Being ,Ki-67 Antigen ,Cross-Sectional Studies ,biology.protein ,Sexually Transmitted Infections ,RNA ,business ,Digestive Diseases ,Precancerous Conditions ,Biomarkers ,Follow-Up Studies - Abstract
Author(s): Wentzensen, Nicolas; Follansbee, Stephen; Borgonovo, Sylvia; Tokugawa, Diane; Schwartz, Lauren; Lorey, Thomas S; Sahasrabuddhe, Vikrant V; Lamere, Brandon; Gage, Julia C; Fetterman, Barbara; Darragh, Teresa M; Castle, Philip E | Abstract: ObjectiveAnal cancer incidence is high in HIV-infected MSM. Screening for anal intraepithelial lesions and cancers is performed at specialized clinics and relies on high-resolution anoscopy (HRA) and anal cytology. Both approaches have limited reproducibility and sensitivity for detecting anal cancer precursors. We evaluated biomarkers for human papillomavirus (HPV)-related disease in a population of HIV-infected MSM.MethodsA cross-sectional screening study with passive follow-up included 363 MSM followed at a HIV/AIDS clinic. All men had anal cytology samples taken and were evaluated using HRA and anal biopsies. Using a composite endpoint of biopsy results and cytology, we compared the performance of HPV16/18 genotyping, HPVE6/E7 mRNA expression, and p16/Ki-67 cytology to detect high-grade anal intraepithelial neoplasias (AINs).ResultsFor all biomarkers analyzed, there was a significant trend of increasing percentage of men testing positive with increasing severity of disease (P l 0.001). HPV DNA testing had the highest sensitivity for anal intraepithelial neoplasia grade 2 and anal intraepithelial neoplasia grade 3 (AIN3), followed by p16/Ki-67, HPVE6/E7 mRNA testing, and HPV16/18 genotyping. The highest Youden's index was observed for HPVE6/E7 mRNA testing, followed by HPV16/18 genotyping, p16/Ki-67 cytology, and HPV DNA testing. Increasing the threshold for positivity of p16/Ki-67 to five or more positive cells led to significantly higher specificity, but unchanged sensitivity for detecting AIN3.ConclusionMolecular features of anal disease categories are similar to those of corresponding cervical lesions. Biomarkers evaluated for cervical cancer screening may be used for primary anal cancer screening or to decide who should require immediate treatment vs. expectant management.
- Published
- 2012
46. Safety Against Cervical Precancer and Cancer Following Negative Human Papillomavirus and Papanicolaou Test Results in Human Immunodeficiency Virus–Infected Women
- Author
-
Nancy Poitras, Barbara Fetterman, Walter Kinney, Thomas Lorey, and Philip E. Castle
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Time Factors ,Cervical precancer ,Human immunodeficiency virus (HIV) ,Uterine Cervical Neoplasms ,Alphapapillomavirus ,medicine.disease_cause ,Risk Assessment ,California ,Risk Factors ,Internal medicine ,HIV Seropositivity ,Internal Medicine ,medicine ,Humans ,Human papillomavirus ,Early Detection of Cancer ,Aged ,Vaginal Smears ,business.industry ,Cancer ,Papanicolaou Test ,Middle Aged ,Uterine Cervical Dysplasia ,medicine.disease ,Population Surveillance ,Carcinoma, Squamous Cell ,Female ,business ,Precancerous Conditions - Published
- 2012
47. Interrater agreement of anal cytology
- Author
-
Teresa M, Darragh, Diane, Tokugawa, Philip E, Castle, Stephen, Follansbee, Sylvia, Borgonovo, Brandon J, LaMere, Lauren, Schwartz, Julia C, Gage, Barbara, Fetterman, Thomas, Lorey, and Nicolas, Wentzensen
- Subjects
Adult ,Male ,Observer Variation ,Cytodiagnosis ,Incidence ,Biopsy, Needle ,Papillomavirus Infections ,Reproducibility of Results ,HIV Infections ,Middle Aged ,Anus Neoplasms ,Immunohistochemistry ,United States ,Article ,Cohort Studies ,Risk Factors ,HIV Seropositivity ,Biomarkers, Tumor ,Humans ,Homosexuality, Male ,Papillomaviridae ,Precancerous Conditions ,Early Detection of Cancer ,Aged - Abstract
The majority of anal cancers are caused by persistent infections with carcinogenic human papillomaviruses (HPV). Similar to cervical carcinogenesis, the progression from HPV infection to anal cancer occurs through precancerous lesions that can be treated to prevent invasion. In analogy to cervical cytology, anal cytology has been proposed as a screening tool for anal cancer precursors in high-risk populations.The authors analyzed the interobserver reproducibility of anal cytology in a population of 363 human immunodeficiency virus (HIV)-infected men who have sex with men (MSM). Liquid-based cytology (LBC) specimens were collected in the anal dysplasia clinic before the performance of high-resolution anoscopy on all patients. Papanicolaou-stained LBC slides were evaluated by 2 cytopathologists, each of whom was blinded to the clinical outcome and the other pathologist's results, using the revised Bethesda terminology.Overall agreement between the 2 observers was 66% (kappa, 0.54; linear-weighted kappa, 0.69). Using dichotomizing cytology results (atypical squamous cells of undetermined significance [ASC-US] or worse vs less than ASC-US), the agreement increased to 86% (kappa, 0.69). An increasing likelihood of testing positive for markers associated with HPV-related transformation, p16/Ki-67, and HPV oncogene messenger RNA was observed, with increasing severity of cytology results noted both for individual cytologists and for consensus cytology interpretation (P value for trend [p(trend)].0001 for all).Moderate to good agreement was observed between 2 cytopathologists evaluating anal cytology samples collected from HIV-positive MSM. A higher severity of anal cytology was associated with biomarkers of anal precancerous lesions. Anal cytology may be used for anal cancer screening in high-risk populations, and biomarkers of HPV-related transformation can serve as quality control for anal cytology.
- Published
- 2012
48. A general binomial regression model to estimate standardized risk differences from binary response data
- Author
-
Stephanie A, Kovalchik, Ravi, Varadhan, Barbara, Fetterman, Nancy E, Poitras, Sholom, Wacholder, and Hormuzd A, Katki
- Subjects
Adult ,Vaginal Smears ,Likelihood Functions ,Models, Statistical ,Uterine Cervical Neoplasms ,Biostatistics ,Middle Aged ,Uterine Cervical Dysplasia ,Article ,Human Papillomavirus DNA Tests ,Risk Factors ,Case-Control Studies ,Linear Models ,Humans ,Female ,Algorithms ,Software - Abstract
Estimates of absolute risks and risk differences are necessary for evaluating the clinical and population impact of biomedical research findings. We have developed a linear-expit regression model (LEXPIT) to incorporate linear and nonlinear risk effects to estimate absolute risk from studies of a binary outcome. The LEXPIT is a generalization of both the binomial linear and logistic regression models. The coefficients of the LEXPIT linear terms estimate adjusted risk differences, whereas the exponentiated nonlinear terms estimate residual odds ratios. The LEXPIT could be particularly useful for epidemiological studies of risk association, where adjustment for multiple confounding variables is common. We present a constrained maximum likelihood estimation algorithm that ensures the feasibility of risk estimates of the LEXPIT model and describe procedures for defining the feasible region of the parameter space, judging convergence, and evaluating boundary cases. Simulations demonstrate that the methodology is computationally robust and yields feasible, consistent estimators. We applied the LEXPIT model to estimate the absolute 5-year risk of cervical precancer or cancer associated with different Pap and human papillomavirus test results in 167,171 women undergoing screening at Kaiser Permanente Northern California. The LEXPIT model found an increased risk due to abnormal Pap test in human papillomavirus-negative that was not detected with logistic regression. Our R package blm provides free and easy-to-use software for fitting the LEXPIT model.
- Published
- 2012
49. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice
- Author
-
Barbara Fetterman, Thomas Lorey, Franklin Demuth, Hormuzd A. Katki, Walter Kinney, Philip E. Castle, Nancy E. Poitras, Li C. Cheung, Mark Schiffman, and Sholom Wacholder
- Subjects
Adult ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Cervix Uteri ,Cervical intraepithelial neoplasia ,Risk Factors ,Cytology ,Medicine ,Humans ,Mass Screening ,Cumulative incidence ,Longitudinal Studies ,Mass screening ,Aged ,Colposcopy ,Cervical cancer ,Gynecology ,Aged, 80 and over ,Vaginal Smears ,medicine.diagnostic_test ,business.industry ,Obstetrics ,Incidence (epidemiology) ,Papillomavirus Infections ,Cancer ,Middle Aged ,medicine.disease ,Oncology ,Female ,business ,Follow-Up Studies ,Papanicolaou Test - Abstract
Concurrent testing for human papillomavirus (HPV) and cervical cytology (co-testing) is an approved alternative to cytology alone in women aged 30 years and older. We aimed to assess the safety in routine clinical practice of 3-year screening intervals for women testing negative for HPV with normal cytology and to assess if co-testing can identify women at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or worse over 5 years.We assessed the 5-year cumulative incidence, starting in 2003-05, of cervical cancer and CIN3 or worse for 331,818 women aged 30 years and older who enrolled in co-testing at Kaiser Permanente Northern California (Berkeley, CA, USA) and had adequate enrolment co-test results. Follow-up continued until Dec 31, 2009. We defined cumulative incidence to include prevalence at enrolment and incidence after enrolment. Prevalence at enrolment was defined as the ratio of women diagnosed with each outcome on the biopsy visit immediately after their enrolment screening visit to the total enrolled women. At screening visits only HPV test and Pap smear samples were collected, and at biopsy visits colposcopically directed biopsies were taken. To estimate post-enrolment incidence, we used Weibull survival models.In 315,061 women negative by HPV testing, the 5-year cumulative incidence of cancer was 3.8 per 100,000 women per year, slightly higher than for the 306,969 who were both negative by HPV and Pap testing (3.2 per 100,000), and half the cancer risk of the 319,177 who were negative by Pap testing (7.5 per 100,000). 313,465 (99.5%) women negative by HPV testing had either normal cytology or equivocal abnormalities. Abnormal cytology greatly increased cumulative incidence of CIN3 or worse over 5 years for the 16,757 positive by HPV testing (12.1%vs 5.9%; p0.0001). By contrast, although statistically significant, abnormal cytology did not increase 5-year risk of CIN3 or worse for women negative by HPV testing to a substantial level (0.86%vs 0.16%; p=0.004). 12,208 (73%) of the women positive by HPV testing had no cytological abnormality, and these women had 258 (35%) of 747 CIN3 or adenocarcinoma in situ, [corrected] 25 (29%) of 87 cancers, and 17 (63%) of 27 adenocarcinomas.For women aged 30 years and older in routine clinical practice who are negative by co-testing (both HPV and cytology), 3-year screening intervals were safe because a single negative test for HPV was sufficient to reassure against cervical cancer over 5 years. Incorporating HPV testing with cytology also resulted in earlier identification of women at high risk of cervical cancer, especially adenocarcinoma. Testing for HPV without adjunctive cytology might be sufficiently sensitive for primary screening for cervical cancer.Intramural Research Program of the US National Cancer Institute/NIH/DHHS, and the American Cancer Society.
- Published
- 2011
50. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test
- Author
-
Ruth Shaber, Franklin Demuth, Mark Schiffman, Barbara Fetterman, Walter Kinney, Nancy Poitras, Philip E. Castle, and Thomas Lorey
- Subjects
Human Papillomavirus Positive ,Adult ,Risk ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,California ,medicine ,Humans ,Mass Screening ,Cumulative incidence ,Risk factor ,Gynecology ,Cervical cancer ,Vaginal Smears ,Obstetrics ,business.industry ,Papillomavirus Infections ,Absolute risk reduction ,HPV infection ,Obstetrics and Gynecology ,medicine.disease ,Uterine Cervical Dysplasia ,female genital diseases and pregnancy complications ,Confidence interval ,Relative risk ,Female ,business - Abstract
OBJECTIVE: To explore the effect of screening history on the risk of cervical precancer and cancer after an human papillomavirus (HPV)―positive test. METHODS: A large health maintenance organization introduced cytology and HPV cotesting into routine clinical practice in 2003. We selected women aged 30 and older who tested HPV positive, cytology negative between January 2006 and December 2008 who had any clinical follow-up documented before January 2010 (n=26,799). The 1-year and 4-year cumulative incidence rates and rate ratios for cervical intraepithelial neoplasia grade 2 or higher (CIN 2+) with 95% confidence intervals (95% CIs) were calculated as estimates of absolute risk and relative risk, respectively. Results were stratified on immediate past HPV test and Pap results. RESULTS: Without consideration of past screening round, the 1-year and 4-year cumulative incidence rates for CIN 2+ after an HPV-positive, Pap-negative result were 2.83 (95% CI 2.55-3.12) and 7.89 (95% CI 7.00-8.78). However, risks varied substantially by past screening result. For example, the 4-year risk of CIN2+ was greater for women who had a past HPV-positive, Pap-negative result (cumulative incidence rate=11.7 9 , 95% CI 10.22-13.36) compared with those who had HPV-negative, Pap-negative result (cumulative incidence rate= 4 . 56 , 95% CI 3.43-5.69; cumulative incidence rate ratio= 2 . 59 , 95% CI 2.30-2.87). CONCLUSION: Because cervical precancer is associated with persistent HPV infection, the risk associated with an HPV-positive test can vary significantly depending on the immediate past screening round. Optimizing screening programs will require knowledge of screening history.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.